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Résumé 
Contexte: Les études cliniques ont démontré que les statines réduisent les événements 
cérébrovasculaires incluant les accidents vasculaires cérébraux ischémiques. Selon les 
études observationnelles, après un an de traitement seulement 40% des patients prennent au 
moins 80% des doses prescrites et le tiers des patients cessent leur traitement. 
Objectifs: Évaluer l'impact de l'adhésion aux statines sur la survenue de maladie 
cérébrovasculaire chez des patients en prévention primaire. 
Méthodes: Une cohorte de 112 092 patients a été construite à partir des bases de données 
de la RAMQ et de Med-Echo. Tous les patients âgés de 45 à 85 ans sans maladies 
cardiovasculaires ayant nouvellement débuté un traitement avec statines entre 1999 et 2004 
étaient admissibles. Un devis cas-témoin niché dans une cohorte a été utilisé pour évaluer le 
risque de maladie cérébrovasculaire. Chaque cas était apparié avec 15 témoins sur l'âge et 
le temps de suivi. Le niveau d'adhésion était reporté comme le pourcentage de doses 
prescrites utilisé durant la période de suivi. Des modèles de régression logistique 
conditionnelle ajustés pour plusieurs covariables ont été utilisés pour estimer le rapport de 
cote de maladie cérébrovasculaire. 
Résultats: Les patients avaient en moyenne 63 ans, 49% des patients souffraient 
d'hypertension, 21 % étaient diabétiques et 41 % étaient des hommes. Une haute adhérence 
aux statines était associée avec une diminution de maladie cérébrovasculaire (RR=0.75, 
0.67-0.85). Les facteurs de risque pour la maladie cérébrovasculaire étaient le sexe 
masculin, le statut socio-économique faible, le diabète, l'hypertension, un indice de maladie 
chronique élevé et le développement d'une maladie cardiovasculaire durant le suivi. 
Conclusion: Nos résultats démontrent qu'une adhésion ~80% pendant au moins une année 
réduit le risque de maladie cérébrovasculaire par rapport à une adhésion de <20%. 
Mots-clés: statines, maladie cérébrovasculaire, adhésion, prévention primaire, cas-témoin 
niché dans une cohorte, efficacité en situation réelle 
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Abstract 
Background: Clinical trials have demonstrated that statins can reduce cerebrovascular 
events inc1uding ischemic stroke. Observational studies have reported that after one year of 
treatment, only 40% of patients take at least 80% of their prescribed medication and that a 
third of patients stop their therapy. 
Objective: The aim of this study was to evaluate the impact of statin adherence on the rate 
of cerebrovascular disease (CD) among patients in the primary prevention setting. 
Methods: A cohort of 112 092 patients was reconstructed using the RAMQ and Med-Echo 
databases. All patients without cardiovascular disease aged 45 to 85 years old who were 
newly treated with statins between 1999 and 2004 were eligible. A nested case-control 
design was used to study the occurrence of CD. Every case was matched for age and 
follow-up period with up to 15 controls. Adherence level was reported as a medication 
possession ratio (MPR). Conditional logis tic regression models were used to estimate the 
rate ratio (RR) of CD adjusting for several covariables. 
Results: The mean patient age was 63 years, 49% had hypertension, 21 % had diabetes, and 
41 % were males. A high level of adherence to a statin regimen was associated with 
reduction of CD (RR: 0.75; 0.67-0.85). Risk factors for CD were male gender, being a 
welfare recipient, hypertension, diabetes, higher chronic disease score and the development 
of cardiovascular diseases during follow-up. 
Conclusions: Our study indicates that an adherence of 2:80% for more than 1 year reduces 
the occurrence of CD compared to an adherence of <20%. 
Keywords: statins, cerebrovascular disease, adherence, primary prevention, nested case-
control, effectiveness in real-life practice 
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Cardiovascular disease (CVD) is the first cause of mortality in Canada.' It places a 
significant burden on the health care system more than any other illness. In 1998, Health 
Canada estimated the direct and indirect costs of cardiovascular disease for the Canadian 
economy to be over $18 billion a year, which represents about 12% of the total cost of aIl 
illnesses. Furthermore, almost 40% of Canadians will develop sorne form of heart disease 
or stroke over their lifetime. 1 
The main risk factors for heart disease and stroke are high cholesterol, smoking, 
physical inactivity, obesity, high blood pressure and diabetes. Eight in ten Canadians have 
at least one risk factor for cardiovascular disease and Il % have at least three.' Although 
changing lifèstyle habits reduces the risk for cardiovascular disease, drug therapy may also 
be necessary. HMG CoA reductase inhibitors, also known as statins, are prescribed to treat 
patients with high blood cholesterol levels. Statins reduce the level of LDL cholesterol, 
which is a known marker for cardiovascular disease. Several randomised controlled trials 
(RCT) as well as meta-analyses have shown that statins reduce the risk of CVD incidence 
and mortality, in primary as weil as in secondary prevention.2.8 In addition, a few RCTs and 
meta-analyses have also shown that statins can reduce the risk of stroke.4, 9-11 However, a 
recent RCT found that statins reduce the risk of ischemic stroke, but increase the risk of 
hemorrhagic stroke. 12 
Moreover, there is strong clinical evidence about the benefits of statins, but target 
cholesterol levels are not reached within the population. Less than 50% of patients with 
heart disease are actually receiving statins and only 20 to 30% of these patients achieve an 
LDL of less than 2.5 mmollL. 13 This might be explained by a low adherence or persistence 
to statin therapy. As a matter of fact, observational studies have revealed much lower statin 
adherence and persistence compared to the ones found in clinical trials. 14, 15 At this 
moment, no data are available on the impact of non-optimal statin use on cerebrovascular 
disease prevention in a real-life setting. In the context of an aging population and increasing 
health costs, it is imperative to evaluate the impact of non-optimal drug use. Therefore, the 
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main objective of this study is to evaluate the impact of statin adherence on cerebrovascular 
disease among patients 45 to 85 years old without cardiovascular diseases. 
LITERATURE REVIEW 
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1. PREV ALENCE 
Cardiovascular diseases (CVD) are the number one cause of hospitalization among 
men and women in Canada, representing 18% of aIl hospitalizations. 1 They also account for 
36% of aIl deaths in Canada. 1 Of aIl cardiovascular deaths, 54% are due to coronary artery 
disease and 21 % are due to stroke. There are between 40,000 to 50,000 strokes in Canada 
each year and they are the fourth leading cause of death (7% of aIl deaths). Stroke is also 
the second largest contributor to hospital care costs for CVD (17.2% of CVD hospital 
costs) and it costs the Canadian economy $2.7 billion a year. 1 Canadians are at high risk of 
CVD due to a high prevalence of risk factors in the population. 1 Indeed, 80% of Canadians 
have at least one of the following risk factor for CVD, while Il % have at least three: high 
cholesterol, smoking, physical inactivity, obesity, high blood pressure and diabetes. 1 
Furthermore, 6% of Canadian adults and 25% of people 70 years of age and older report 
having he art problems. 1 According to the 1985-1990 Heart Health Surveys, 45% of men 
and 43% of women had a total plasma cholesterol level above the recommended level of 
5.2 mmollL. 1 
2. CARDIOV ASCULAR RISK FACTORS 
The Canadian guidelines for the management and treatment of dyslipidemia use the 
Framingham study equations published in the NCEP A TP III guidelines. 16 These guidelines 
use data from the Framingham study to establish CVD risk. The most important risk factors 
are age, sex, high cholesterol, smoking, physical inactivity, obesity, high blood pressure, 
family history of CVD and diabetes. The most recent Canadian guidelines (2006) have 
established three risk groups: low, moderate and high. 16 These risk groups are based on the 
10-year risk of coronary artery disease (CAD) related death or nonfatal myocardial 
infarction (MI). 
Age and sex are important risk factors for CAD and stroke. As age increases, so do 
rates of CAD and at younger ages, men have a much higher risk of developing a CAD or 
stroke than women. Women tend to develop CAD 10 years after men, but risk levels 
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become similar a few years after menopause. 1 After the age of 55, the stroke rate doubles in 
both men and women for each successive 10 years. 17 
The INTERHEART case-control study investigated the relationship between risk 
factors and CAD in 52 different countries. 18 Nine risk factors were evaluated: smoking, 
hypertension, diabetes, waistlhip ratio, dietary patterns, physical activity, consumption of 
alcohol, blood apolipoproteins and psychosocial factors. The analysis included 12461 
cases of acute myocardial infarction and 14637 contrcils from 52 countries. Together, these 
nine risk factors accounted for 90% of the population attributable risk in men and 94% in 
women. The most important risk factors in order were: raised ApoB/ ApoA1 ratio (OR= 
3.25, 99% CI 2.81-3.76), smoking (OR=2.87, 99% CI 2.58-3.19), psychosocial factors 
(OR= 2.67, 99% CI 2.21-3.22), diabetes (OR= 2.37, 99% CI 2.07-2.71), hypertension (OR= 
1.91, 99% CI 1.74-2.10) and abdominal obesity (OR=1.12, 99% CI 1.01-1.25). The most 
important protective factors in order were: daily consumption of fruits and vegetables (OR= 
0.70, 99% CI 0.62-0.79), regular physical activity (OR= 0.86, 99% CI 0.76-0.97) and 
regular alcohol consumption as defined by 3 to 4 consumptions a week (OR= 0.91,99% CI 
0.82-1.02). However, the odds ratios of certain risk factors varied by sex. The increased 
risk associated with diabetes and hypertension as weIl as the protective effect of exercise 
and alcohol were greater in women than in men. This study showed that the two most 
important risk factors, smoking and abnormal lipids, were present worldwide and 
accounted for about two-thirds of the population attributable risk. Furthermore, this study 
suggests that over 90% of the risk of an acute myocardial infarction in a population can be 
predicted using the nine risk factors included in this analysis. 
McCormack et al. created nomograms that could help clinicians estimate the risk of 
cardiovascular and cerebrovascular events for an individual patient. 19 They display the risks 
relative to age, sex and other risk factors of cardiovascular events over a 5 or 10 year period 
and of cerebrovascular events over a 10 year period in patients with no history of 
cerebrovascular disease. The nomograms were created using data from the Framingham 
Study. The risk factors considered for cerebrovascular disease were age, sex, blood 
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pressure, diabetes, smoking, atrial fibrillation and left-ventricular hypertrophy. The most 
important risk factors for men were left-ventricular hypertrophy (OR = 5), atrial fibrillation 
(OR=4), smoking (OR=3) and diabetes (OR=2). For women, they were atrial fibrillation 
(OR=6), left-ventricular hypertrophy (OR=4), smoking (OR=3) and diabetes (OR=3). Odds 
ratios for hypertension varied according to the severity and ranged from 2 to 10 for both 
sexes. Unfortunately, the authors could not quantify risk factors such as family history, 
sedentary life style, weight or ethnie background for individual patients. 
2.1 Previous cardiovascular events 
Patients with a previous stroke have a 6 times greater risk of a recurrent stroke than 
of a first-ever stroke in the general population of the same age and sex.20 Furthermore, after 
the first year of the first stroke, the annual risk of recurrent stroke is approximately 4%.20 
These patients also have an annual risk of 2.2% for myocardial infarction and about 10% 
for death, which is about twice the expected rate.21 -23 In comparison, patients with a 
previous myocardial infarction are 5 to 7 times at greater risk of a second coronary event 
and are 3 to 4 times at greater risk of having a stroke.24, 25 Patients with peripheral arterial 
disease (PAD) are 2 to 6 times more at risk of fatal myocardial infarction and CAD death 
and are at 2 to 4 times greater risk for stroke.26 
2.2 Farnily history of cardiovascular disease 
A family history of CAD, which is present before age 60 and is determined 
unambiguously in first-degree relatives (parents, brothers, sisters), increases an individual's 
risk by 1.7 to 2.0 times.27 
2.3 Cornorbidities 
The major risk factors for atherosclerosis are high plasma LDL, low plasma HDL, 
cigarette smoking, hypertension, and diabetes mellitus. These factors disturb the normal 
functions of the vascular endothelium and are important risk factors of CVD.28 
Hypertension leads to concentric left ventricular hypertrophy, which accelerates CAD. 
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Furthermore, it is the single most important modifiable risk factor for stroke. 17 The relative 
risk of stroke is approximately 4 when hypertension is defined as systolic blood pressure 
2:160 mm Hg and/or diastolic blood pressure 2: 95 mm Hg. However, extensive clinical 
trial evidence has established that antihypertensive drugs can reduce the risk of CAD, 
stroke and he art failure. 29 
Diabetes mellitus is a CAD risk equivalent and most patients with diabetes mellitus 
die of atherosclerosis and its complications. Diabetic patients often have near average LDL 
levels, although the LDL particles tend to be smaller and denser and therefore more 
atherogenic. These patients frequently have low HDL and elevated triglyceride levels as 
wel1.29 CAD events and mortality are two to four times greater in patients with type 2 
diabetes. Type 2 diabetes patients without a prior myocardial infarction have a similar risk 
for CAD events as nondiabetic individuals who have had a prior myocardial infarction. 30 
In addition to CAD, patients with diabetes mellitus have a threefold increase risk for 
stroke.30 A recent meta-analysis could not prove that improved glucose control reduced the 
risk of macrovascular complications (CAD, peripheral arterial disease, cerebrovascular 
disease). However, it did find that treating hypertension and dyslipidemia significantly 
reduces the risk of primary and secondary macrovascular events in patients with type 2 
diabetes. 31 On the other hand, randomized clinical trials of diabetic patients have 
demonstrated that a reduction in chronic hyperglycemia prevents or delays microvascular 
complications (retinopathy, neuropathy, nephropathy).30 
2.4 Lifestyle habits 
Cigarette smoking promotes atherosclerosis, platelet aggregation and vascular 
occlusion and it causes 20 to 30% of CAD as weIl as 10% of occlusive cerebrovascular 
disease. It also increases the risk of stroke by nearly two times, with a clear dose-response 
relation. 17 Furthermore, there is a multiplicative interaction between cigarette smoking and 
other cardiac risk factors. 32 Benefits of cessation can be seen rather quickly. Indeed, 
cessation reduces the risk of a second CAD within 6 to 12 months. Rates of first myocardial 
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infarction or death from CAD decline within the first few years and after 15 years of 
cessation, the risk becomes equivalent to those who have never smoked. 32 
Obesity is an independent risk factor for CVD, but it is also associated with 
dyslipidemia, hypertension and diabetes. 33 Obesity is measured by determining the waist-
to-hip ratio, with a ratio >0.9 in women and >1.0 in men being abnorma1.33 Another way to 
measure obesity is the body mass index, which is equal to weightJheight2 (in kg/m2). In this 
case, a body mass index of 30 is most commonly used as a threshold for obesity in both 
men and women.33 In Canada, 15% of adults are obese. The greater the body mass index, 
the greater the risk of CAD and stroke. 1 
A sedentary lifestyle is also another risk factor for CVD. I Regular physical activity 
can reduce overall cardiovascular risk by reducing body weight as well as improving 
cholesterol levels, diabetes and blood pressure. Canadian guidelines recommend at least 60 
minutes of light physical activity or 30 minutes of moderate physical activity each day. In 
2000, 57% of Canadian adults were physically inactive. 1 In addition, more women than 
men were physically inactive. 1 
Inadequate consumption of fruits and vegetables increases the risk of CVD. I Fresh 
fruits and vegetables are a source of vitamins, anti-oxidants and fiber. They are also a 
source of potassium, which has been shown to be protective against strokes. 1 In 2000, 62% 
of Canadians over the age of 12 consumed less than the recommended amount of 5 to 10 
daily servings of fresh fruits and vegetables. 1 
2.5 Gender and menopause 
CAD develops in women ten years later than in men. Men are also at higher risk of 
stroke. 1 Compared to premenopausal women, men have a greater risk of CAD. I• 29 
However, CAD risk accelerates in women after menopause. Premenopausal women have 
higher HDL cholesterol levels compared with those of men. After menopause, HDL 
cholesterol values fall in concert with increased CAD risk.29 Multiple observational studies 
suggested that estrogen therapy might reduce CAD risk.29 The Heart and 
EstrogenIProgestin Replacement Study (HERS) randomly assigned postmenopausal women 
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to an estrogenlprogestin cornbination for secondary prevention of CAD.34 During an 
average follow-up of 4.1 years, it found no overall reduction in CAD between the treatrnent 
and placebo groups. A further analysis also found no significant effect on the risk of 
stroke.35 Recently, the Wornen's Health Initiative (WHI) trial, a randornized controlled 
prirnary prevention trial for CAD, was halted because of a significant increase in adverse 
events, CAD events (HR= 1.29,95% CI 1.02-1.63), stroke (HR= 1.41,95% CI 1.07-1.85), 
and breast cancer (HR= 1.26, 95% CI 1.00-1.59) in the estrogenlprogestin group.36 
2.6 Socio-economic status 
The prevalence of diabetes, hypertension and smoking is higher arnong social 
rninorities, low-incorne and less educated groupS.37 Furtherrnore, rnernbers of these 
populations tend to have low adherence to their rnedications, which rnight be due to 
econornic and access barriers, lack of social support, differences in health beliefs and 
cultural norrns as weIl as lower disease specifie knowledge and education al background.38 
3. CLINICAL EFFICACY OF ST ATINS ON STROKE 
Clinical trials have shown significant benefits of statins in both prirnary and 
secondary prevention of CAD.6, 7, 10, Il, 39-43 In addition, a few clinical trials have also 
reported a reduced incidence of stroke.6, 9-11, 40 The risk reduction in stroke was first seen in 
trials for the secondary prevention of CAD. The Scandinavian Sirnvastatin Survival Study 
(4S), CARE, the Long-Terrn Intervention with Pravastatin in Ischaernic Disease (LIPID) 
study and the Heart Protection Study (HPS) found that statins reduced the risk of stroke by 
19-31 %.6,10,40,41 The earliest clinical trials to evaluate the efficacy of statins on the prirnary 
. prevention of CAD did not have a sufficient study population to have statistically 
significant results on stroke rate. However, the rnost recent trials, ASCOT and CARDS, 
respectively had a large study population and patients at very high risks of CAD. 
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3.1 Primary prevention of CAD 
The West of Scotland Coronary Prevention Study (WOSCOPS) wanted to 
determine wh ether pravastatin reduced the combined incidence of nonfatal MI and death 
from CAD?9 Patients were men 45 to 64 years of age with hypercholesterolemia and no 
history of MI. A total of 6595 men were randomly assigned pravastatin 40mg or placebo 
and the average follow-up period was 4.9 years. Pravastatin lowered plasma cholesterol 
levels by 20% and LDL cholesterol by 26%, while the risk of nonfatal MI or death from 
CAD was reduced by 31 % (RR=0.69, 95% CI 0.67-0.83). Fatal or nonfatal strokes were 
non significantly reduced by Il % (RR=0.89, 95% CI 0.60-1.33). 
The Air Force/Texas Coronary Atherosc1erosis Prevention Study 
(AFCAPS/TexCAPS) investigated if lovastatin would decrease the rate of a first acute 
major coronary event (fatal or nonfatal MI, unstable angina or sudden cardiac death).7 A 
total of 6605 patients aged 45 to 73 years without clinically evident atherosc1erotic CVD 
with average total cholesterol and LDL cholesterol levels and below-average HDL 
cholesterol levels were inc1uded in the study. After an average follow-up of 5.2 years, 
lovastatin reduced the risk of a first acute major coronary event by 37% (RR=0.63, 95% CI 
0.50-0.79). Unfortunately, no data on stroke was presented. 
The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) trial 
inc1uded 5804 patients 70 to 82 years old with a history of, or risk factors for CVD.43 After 
an average follow-up of 3.2 years, pravastatin 40mg lowered LDL cholesterol levels by 
34% and reduced the primary endpoint (composite of coronary death, nonfatal MI and fatal 
or nonfatal stroke) by 15% (HR=0.85, 95% CI 0.74-0.97). Among the elderly patients in 
primary prevention, there was no c1ear effect of pravastatin on stroke. 
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial-
Lipid Lowering Trial (ALLHAT-LLT) aimed to determine whether pravastatin compared 
with usual care reduces alI-cause mortality in older, moderately hypercholesterolemic, 
hypertensive participants with at least 1 additional CAD risk factor. 44 A total of 10 355 
patients aged 55 years or older were inc1uded in the study and 86% of patients did not have 
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CAD at baseline. Mean folIow-up was 4.8 years. During the trial, 32% of usual care 
participants with CAD and 29% without CAD started taking lipid-Iowering drugs. 
Pravastatin did not reduce alI-cause mortality (RR=0.99, 95% CI 0.89-1.11) or CAD 
(RR=O. 91, 95% CI 0.79-1.04). Furthermore, no reduction in stroke was found (RR=O. 91, 
95% CI 0.75-1.09). 
The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) was a multicentre 
randomised trial that compared two antihypertensive treatments for the prevention of CAD 
events in hypertensive patients with no history of CAD.9 The Lipid Lowering Arm of this 
study (ASCOT-LLA) examined the effect of atorvastatin on the prevention of CAD and 
stroke events in hypertensive patients with average or lower than average cholesterol 
concentrations. Of the 19342 patients in the ASCOT trial, 10 305 were randomly assigned 
atorvastatin lOmg or placebo. To be eligible for the lipid lowering arm, patients had to be 
40 to 79 years of age, hypertensive, have a non-fasting total cholesterol concentration of 6.5 
mmollL or less and not currently taking a statin or a fibrate. Moreover, patients had to have 
at least three of the following CVD risk factors: left-ventricular hypertrophy, other 
specified abnormalities on electrocardiogram, type 2 diabetes, peripheral arterial disease, 
previous stroke or transient ischaemic attack, male sex, age 55 years or older, 
microalbuminuria or proteinuria, smoking, ratio of plasma total cholesterol to HDL-
cholesterol of 6 or higher, or premature family history of CAD. Patients with a previous 
myocardial infarction, currently treated angina, a cerebrovascular event within the previous 
3 months, fasting triglycerides higher than 4·5 mmollL, he art failure or uncontrolled 
arrhythmias were excluded from the study. Patients were mostly male (81%) with a mean 
age of 63 years and the average number of additional CVD risk factors was 3.7. A quarter 
of the patients had diabetes, 10% had a previous stroke or TIA and 17% were using aspirin. 
After a median folIow-up period of 3.3 years, the primary endpoint of non fatal myocardial 
infarction (including silent myocardial infarction) and fatal CAD was significantly reduced 
by 36% (HR=0.64, 95% CI 0.50-0.83). This benefit was evident within the first year of 
treatment. Furthermore, atorvastatin also significantly reduced four of the seven secondary 
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endpoints: total CVD events and procedures (HR=0.79, 95% CI 0.69-0.90), total CAD 
events (HR=0.71, 95% CI 0.59-0.86), non fatal myocardial infarction (excluding silent 
myocardial infarction) plus fatal CAD (HR=0.62, 95% CI 0.47-0.81) as weIl as fatal and 
nonfatal strokes of aIl kinds (HR=0.73, 95% CI 0.56-0.96). Cardiovascular and alI-cause 
mortality were both non significantly reduced by about 10%. By the end of the study, 
atorvastatin lowered LDL cholesterol in patients by 1.0 mmol/L. 
A post-hoc analysis of data from the ASCOT -LLA trial was performed ,in order to 
determine the timing of CVD risk reduction.45 Benefits for reduction in CAD events were 
found as early as 30 days after randomisation. However, significant benefits only began to 
be observed at 90 days and were maintained through the end of the study. Risk reductions 
for stroke were constant throughout the trial, but benefits began to be significant at 2 years 
of treatment. These results suggest that a minimal treatment period of 3 months is required 
with atorvastatin in order to see significant results for a reduction in CAD events while a 2 
year treatment period is required for a significant reduction in stroke events. 
The CoIlaborative Atorvastatin Diabetes Study (CARDS) was a multicentre 
randomised piacebo-controlled trial. ll The objective was to evaluate the effectiveness of 
atorvastatin lOmg in the primary prevention of major CVD events in patients with type 2 
diabetes without high concentrations of LDL cholesterol. Eligible patients had to be 40 to 
75 years old with type 2 diabetes diagnosed at least 6 months before study entry. They also 
needed to have one of the following: hypertension, retinopathy, albuminuria or currently 
smoking. Patients who were smoking were counselled to quit. Their me an serum LDL 
levels during the baseline visits also had to be 4.14 mmol/L or lower and their serum 
triglycerides levels had to be 6.78 mmollL or less. Patients were exc1uded if they had any 
past history of myocardial infarction, angina, coronary vascular surgery, cerebrovascular 
accident or severe peripheral vascular disease. In total, 2838 patients were randomised. 
Patients were mainly men (68%) and had a mean age of 62 years. At entry, 68% of patients 
had one additional entry criteria risk factor, 30% had two, 6% had three and 1% had four. 
The primary endpoint consisted of acute CAD events, coronary revascularisation 
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procedures or stroke. An acute CAD event was defined as a myocardial infarction 
(including silent myocardial infarction), unstable angina, acute coronary heart disease death 
or resuscitated cardiac arrest. Following a median period of observation of 4.0 years, 
atorvastatin significantly reduced major cardiovascular events by 37% (HR=0.63, 95% CI 
0.48-0.83). When analysed separately, there was a reduction of 36% in acute coronary 
events (HR=0.64, 95% CI 0.45-0.91), 48% in stroke (HR=0.52, 95% CI 0.31-0.89) and a 
non significant 31% in coronary revascularisation events (HR=0.69, 95% CI 0.56-1.16). 
The effect of atorvastatin did not vary by the pre-treatment cholesterol amount. The results 
of this study show that atorvastatin is effective in reducing major cardiovascular events in 
diabetic patients with no history of CVD and without high levels of LDL. 
3.2 Secondary prevention of stroke 
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) 
study investigated whether statins reduce the risk of stroke after a recent stroke or transient 
ischemic attack. 12 Patients had to be over 18 years of age with no known CAD and have 
had an ischemic or hemorrhagic stroke or transient ischemic attack 1 to 6 months before 
randomisation. Patients with hemorrhagic stroke were included if they were at risk for 
ischemic stroke or CAD. Patients also had to be ambulatory and have LDL levels ranging 
from 2.6 mmol/L to 4.9 mmollL. Exclusion criteria were atrial fibrillation, other cardiac 
sources of embolism and subarachnoid hemorrhage. Furthermore, patients who were taking 
lipid-Iowering drugs had to stop these medications 30 days before the screening phase of 
the study. A total of 4173 patients were randomised to atorvastatin 80mg or placebo and 
they were aIl counselled to follow the National Cholesterol Education Program Step 1 diet 
throughout the study. The median duration of follow-up was 4.9 years. The primary 
endpoint of fatal or nonfatal stroke was reduced by 16% in the treatment group (HR=0.84, 
95% CI 0.71-0.99). Post hoc analyses on the type of stroke occurring during the trial 
indicated significant differences in the treatment effect. Atorvastatin reduced the risk of 
ischemic stroke by 22% (HR=0.78, 95% CI 0.66-0.94) whereas it increased the risk of 
15 
hemorrhagic stroke by 66% (HR=1.66, 95% CI 1.08-2.55). However, the incidence of fatal 
hemorrhagic stroke did not differ significantly between the two groups. 
3.3 Meta-analyses 
The finding of a reduced incidence of stroke by statins aroused interest for stroke 
prevention. In 1997, meta-analyses started to pool data from published trials in order to 
quantify the magnitude of risk reduction provided by statins.46 Since then, several statin 
trials have been published and meta-analyses have continuously been performed. 
Briel M. et al. performed a meta-analysis to assess if lipid-Iowering interventions 
(statins, fibrates, resins, n-3 fatty acids and diet) prevent nonfatal and fatal strokes in 
patients with and without CAD.47 This meta-analysis included aIl randomised controlled 
trial published through August 2002 that had a minimum follow-up of 6 months and data 
on nonfatal and fatal strokes as weIl as total mortality. Trials restricted to patients with 
previous strokes were excluded. The literature search yielded 29 statin trials with a total of 
93 389 participants. Statins reduced nonfatal and fatal stroke by 18% (RR=0.82, 95% CI 
0.76-0.90). The risk of stroke was reduced by 25% (RR=0.75, 95% CI 0.65-0.87) for 
patients with CAD and by 23% (RR=0.77 95% CI 0.62-0.95) for those without CAD. Data 
analysis found no difference in hemorrhagic strokes (RR=1.03, 95% CI 0.49-2.16). These 
results suggest that statins may reduce fatal and nonfatal strokes in patients with or without 
coronary heart disease. 
Thavendiranathan P. et al. performed a meta-analysis to clarify the role of statins in 
the primary prevention of cardiovascular diseases.48 They included randomised controlled 
trials with at least 80% of the subjects with no history of CVD, a follow-up of at least one 
year and more than 100 major cardiovascular events. The primary outcomes for this meta-
analysis were major coronary events (nonfatal myocardial infarction and CAD death) and 
major cerebrovascular events (fatal and nonfatal strokes). Seven trials with 42 848 patients 
were included in the meta-analysis. The mean follow-up of the trials was 4.3 years and 
ninety percent of the subjects had no history of CVD. They found that in the primary 
prevention of CVD, statins reduced the risk of major coronary events by 29% (RR= 0.71, 
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95% CI 0.60-0.83), nonfatal MI by 32% (RR= 0.68, 95% CI 0.56-0.83) and 
revascularisation procedures by 34% (RR= 0.66, 95% CI 0.54-0.80). However, statins 
produced a non significant 23% risk reduction in CAD death (RR= 0.77, 95% CI 0.56-
1.08). They also found that statins reduced the risk of fatal and nonfatal strokes by 14% 
(RR= 0.86,95% CI 0.75-0.97). 
Cheung B. et al. also performed a meta-analysis in order to estimate the effect of 
statins on major coronary events, strokes, ail-cause mortality and non CVD mortality.49 
Criteria for inclusion were English clinical trials published between January 1990 and April 
2003 that had a placebo arm with a folIow-up of at least 3 years and at least 100 major 
coronary events. Ten trials involving 79 494 subjects were included in the meta-analysis. 
They found that statins reduced major coronary events by 27% (RR= 0.73, 95% CI 0.70-
0.77), ail-cause mortality by 15% (RR= 0.85, 95% CI 0.79-0.92) and non cardiovascular 
mortality by 4% (RR= 0.96,95% CI 0.90-1.03). Statins reduced stroke by 18% (RR= 0.82, 
95% CI 0.75-0.90). However, they found that pravastatin reduced strokes by 12% (RR= 
0.88, 95% CI 0.79-0.99) white other statins (simvastatin, lovastatin, atorvastatin and 
fluvastatin) reduced ail strokes (except transient ischemic attacks) by 24% (RR= 0.76, 95% 
CI 0.68-0.84). 
3.4 Relationship between reduction of lipid profile and stroke 
The more recent meta-analyses have not only examined the incidence of stroke in 
patients treated with or without statins, but also the relationship of LDL cholesterol as a 
marker for stroke. 
The meta-analysis performed by Baigent C. et al. was done with data on 90 056 
individuals from 14 randomised trials of statins.5 The mean follow-up period was 5 years. 
At one year, the mean LDL cholesterol differences ranged from 0.35 mmol/L to 1.77 
mmollL, with a mean of 1.09 mmollL. There was a 12% risk reduction in alI-cause 
mortality per mmol/L reduction in LDL cholesterol (RR=Ü.88, 95% Cl 0.84-0.91), which 
reflected a 19% reduction in coronary mortality (RR=0.81, 95% CI 0.76-0.85). There was 
also a 23% risk reduction in myocardial infarction or coronary death (RR=Ü.77, 95% CI 
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0.74--0.80) and a 24% reduction in the need for coronary revascularisation (RR=0.76, 95% 
CI 0.73-0.80). Data were available on a total of 2957 strokes. Among 65 138 participants, 
there were 2282 strokes with information on stroke type. Nine percent were definitel y 
attributed to hemorrhage, 69% were confirmed to be ischemic and 22% were of unknown 
type. Overall, stroke was reduced by 17% (RR=0.83, 95% CI 0.78-0.88) per mmollL lower 
of LDL cholesterol. Ischemie stroke was reduced by 22% (RR=0.78, 99% CI 0.70-0.87) 
per mmollL LDL cholesterol reduction and there was no apparent difference in 
hemorrhagic stroke (RR=1.05, 99% CI 0.78-1.41). The risk reduction in major vascular 
events differed only according to the absolute reduction in LDL cholesterol achieved. 
The primary aim of the meta-analysis performed by Amarenco P. et al. was to 
investigate the effect of statins on stroke incidence and stroke mortality.46 They also studied 
the effect of statins on the incidence of hemorrhagic stroke as weIl as the relationship 
between LDL cholesterol reduction by statins and its effect on stroke incidence. The 
analyses were performed on 26 trials that recruited a total of 97 981 patients. They found 
that statins reduced the risk of stroke by 21 % (OR=0.79; 95% CI 0.73-0.85). Fatal strokes 
were reduced but not significantly by 9% (OR=0.91; 95% CI 0.76-1.10) and there was no 
increase in hemorrhagic strokes (OR=0.90; 95% CI 0.65-1.22). They also found that each 
10% reduction in LDL cholesterol reduced the risk of aIl strokes by 15.6% (95% CI, 6.7 to 
23.6). 
Law MR. et al. performed a meta-analysis to determine the effect of statins on LDL 
cholesterol, coronary artery disease and stroke.50 To do so, they performed three separate 
meta-analyses: the y used 164 short term randomized placebo controlled trials of statins and 
LDL cholesterol reduction (38303 patients), 58 randomised trials of cholesterol lowering 
drugs and CAD events (148321 patients) and nine cohort studies as weil as the 58 trials on 
CAD to study stroke (836 697 patients). Reductions in LDL cholesterol were 2.8 mmolll 
. (60%) with rosuvastatin 80 mg/day, 2.6 mmol/l (55%) with atorvastatin 80 mg/day, 1.8 
mmolll (40%) with atorvastatin 10 mg/day, lovastatin 40 mg/day, simvastatin 40 mg/day, 
or rosuvastatin 5 mg/day. Pravastatin and fluvastatin achieved smaller reductions. For an 
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LDL cholesterol reduction of 1.0 mmol/L the risk of CAD was reduced by Il % (4-18%) in 
the first year oftreatment, 24% (17-30%) in the second year, 33% (28-37%) in years three 
to five and 36% (26-45%) thereafter. CAD was reduced by 20%,31%, and 51% by LDL 
cholesterol reduction (means 0.5 mmol/L, 1.0 mmollL, and 1.6 mmol/L). Lowering LDL 
cholesterol decreased a11 stroke by 10% for a 1 mmollL reduction and 17% for a 1.8 
mmollL reduction. However, wh en evaluating ischemic and hemorrhagic stroke separately, 
there was a 15% (6% to 21 %) decrease in ischemic stroke and a 19% (10% to 29%) 
increase in hemorrhagic stroke per 1 mmol/L reduction in LDL cholesterol. 
4. TREATMENT T ARGETS 
The beneficial effects of statins in the primary and secondary prevention of CVD 
have been well documented in severallarge randomized contro11ed studies.6, 7,10, Il,39-41,43 
Despite the evident benefits achieved by the reduction of LDL, the majority of patients with 
established CVD or hypercholesterolemia fails to reach recommended LDL levels. 
CALIPSO was a cross-sectional observational study involving Canadian physicians 
who were among the top statin prescribers.51 The aim was to assess the profile of patients 
treated with statins and to determine whether they were achieving recommended LDL 
cholesterol targets. Each physician enrolled up to 15 patients with a diagnosis of 
hypercholesterolemia and who had been using a statin for at least 8 weeks. The 3721 
patients enrolled had been treated for an average of 4.3 years. According to the 2003 
Canadian guidelines, 68% of the patients were at high risk of CAD. In addition, 46% of 
patients had established CVD, 34% had diabetes and 60% had hypertension. However, in 
spite of statin therapy, 27% of a11 patients and 36% of those at high risk of CAD had not 
achieved LDL cholesterol targets. 
Baessler A. et al. performed a nested case-control study to evaluate the relationship 
between statin treatment quality and the incidence of CAD (coronary death, non fatal 
myocardial infarction, bypass surgery) over a 30-month follow-up in a cohort of post 
myocardial infarction patients with hypercholesterolaemia.52 A total of 173 cases with a 
CAD and 346 matched controls were included in their analysis. Optimal treatment was 
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defined as patients who had reached LOL cholesterol levels below 115 mg/dl and 
suboptimal as LOL levels above 115 mg/dl. They found that 11.0% of patients were treated 
optimally, 43.4% were treated suboptimally and 45.7% were untreated. They also found 
that the relative risk of future non-fatal myocardial infarction and CAO death associated 
with a suboptimal statin treatment was 2.02 (95% CI 1.04-4.18) compared to optimal statin 
treatment. 
Farahani P. et al. aimed to assess the characteristics of patients associated with the 
use of lipid-Iowering drugs and to assess amongst lipid-Iowering drug users the proportion 
of patients that would meet the 2003 Canadian dyslipidemia management guidelines.53 
Eligible patients were those filling a prescription for any lipid-Iowering therapy in selected 
pharmacies in Ontario, Quebec, British Columbia and Nova Scotia. Patients were 
interviewed over the telephone and physicians who were providing health care to the 
patients were asked to provide information from the patient' s medical record. A total of 
1103 patients were inc1uded in the study and 94% of them were prescribed statin drugs. The 
mean patient age was 64 years and 61 % of patients were being treated for primary 
prevention. Patients had an average of 2.8 CVO risk factors and 86% of patients had at least 
two CVO risk factors. There was a mean lag time of 1.96 years between the diagnosis of 
dyslipidemia and the initiation of drug treatment. Lipid-Iowering therapy was associated 
with a 1.81 mmol/L decrease in LOL cholesterol (p-value < 0.001), although only 73% of 
patients achieved target LDL cholesterol concentrations. 
Petrella RJ. et al evaluated the patient characteristics and lipid-Iowering treatment 
patterns in a cohort representing Canadian primary care practice.54 The Southwestern 
Ontario database was used as the data source. Male and female patients with data available 
from 4 physician visits between April 2000 and Oecember 2003 were inc1uded. In this 
study, a patient was considered to have dyslipidemia if at least two of the following 
conditions were met: (1) physician-diagnosed hyperlipidemia or hypercholesterolemia; (2) 
at least 1 measurement of LOL cholesterol or total cholesterol: HOL cholesterol ratio 
greater than the recommended targets based on lO-year CAO risk; and/or (3) at least 1 
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prescription for a lipid-Iowering drug. Dyslipidemia was identified in 6961 patients and 
their mean age was 64 years. Patients fell mostly into very-high-risk (45.7%) or low-risk 
(31.1 %) categories for CAD. They found that more patients were untreated (63.2%) than 
treated (36.7%) with lipid-Iowering treatments. A total of 73.0% of treated patients were 
prescribed monotherapy with a statin; and of statin prescriptions, most were for atorvastatin 
(51.8%) or simvastatin (29.4%). Among treated patients, 47.2% had not reached target 
cholesterol targets, with fewer women having controlled disease than men (p-value < 
0.017). 
5. ADHERENCE AND PERSISTENCE 
Adherence is defined to be the extent to which patients take medications as 
prescribed by their health care providers. It is measured by the percentage of doses of a 
medication that a patient takes compared to the doses he should be taking in a given period 
of time. An accurate way of measuring ove raIl adherence is the rates of refilling 
prescriptions. This method requires a cIosed pharmacy system as weIl as refill 
measurements at several points in time. Since there is no consensus on what constitutes 
adequate adherence, the eut-off levels of adherence vary by study and investigator. 
Generally, the eut-off point of 80% separates adherent from non-adherent patients. 
However, certain conditions such as treatment of patients with HIV, require an adherence 
to antiretroviral therapy of more than 95% in order to suppress viral replication.55 In 
addition, adherence levels are generally higher among patients with acute conditions than 
those with chronic conditions.55 
Persistence is the duration of time over which a patient continues to take his 
prescribed medication. The most commonly used method for measuring persistence 
quantifies the gaps between prescription refills.56 Each patient has a certain grace period to 
ob tain an addition al refil!. This grace period begins at the end of the supply of the previous 
prescription and depending on the investigators, can vary between 15 and 120 days.56 If a 
patient refills the prescription by the end of the grace period, the patient is cIassified as 
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persistent. However, if a patient does not refill his prescription within the grace period, that 
patient is considered non persistent. 
5.1 Adherence in clinical trials 
Clinical trials represent a highly controlled study environment. Participants are 
followed closely and are encouraged to take their medication. Indeed, withdrawal rates in 
clinical trials vary between 6 and 30% after an average follow-up period of 5 years. 7, 9-11,39-
41 Two large randomized controlled trials reported on adherence levels. The 
AFCAPS/TexCAPS primary prevention trial, which compared lovastatin with placebo, 
reported that 99% of participants adhered to their study regimen for at least 75% of the 
time.7 At trial termination, 71 % of the participants receiving lovastatin were still taking the 
drug. In comparison, the HPS trial reported that 82% of patients in the simvastatin group 
were taking at least 80% of their pills.6 
5.2 Adherence and persistence in a real-life setting 
Observational studies performed with administrative databases give a better 
approximation of adherence and persistence levels in a real-life setting. A retrospective 
cohort study was done in the United-States on 34 501 new users of statins àged 65 years or 
older who were enrolled in the New Jersey Medicaid or Pharmaceutical Assistance to the 
Aged and Disabled programs. 14 Patients had to initiate statin therapy between 1990 and 
1998 and were followed until December 31st 1999. Most patients were white women with 
an average age of 74 years at treatment initiation. In addition, 46% of patients had a history 
of CAD. Adherence to a statin was 79% in the first 3 months of treatment, 56% after 6 
months and 50% after one year. The proportion of patients who were adherent to their statin 
therapy (who toke at least 80% of the prescribed dose) was 60%, 43% and 26% after 3 
months, 6 months and 5 years of treatment, respectively. 
A cohort study using administrative databases was do ne in Ontario to compare the 
2-year persistence following statin therapy initiation in 3 groups of patients: those with 
recent acute coronary syndromes, those with chronic CAD and those without CAD 
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(primary prevention).15 AU patients 66 years or older with a statin prescription between 
J anuary 1 st 1994 and Oecember 31 st 1998 and who did not have a statin prescription in the 
prior year were included in the study. There were 22 379 patients in the acute coronary 
syndromes, 36 106 in the chronic CAO and 85 020 in the primary prevention groups. The 
2-year persistence rates were 40% for patients with acute coronary syndromes, 36% for 
patients with CAO and 25 % for primary prevention patients. Compared to the acute 
coronary syndromes cohort, non persistence was 14% (RR=1.14; 95% CI 1.11-1.16) more 
likely in patients with chronic CAO and almost twice as likely in patients without CAO 
(RR=1.92; 95% CI 1.87-1.96). 
A cohort study using administrative databases in Quebec found very low persistence 
rates as welLs7 The persistence rate was evaluated for patients 50 to 64 years old initiating 
statin therapy between J anuary 1 st 1998 and Oecember 31 st 2000. Patients were excluded if 
they had a statin prescription or if they received antiplatelet drugs or anticoagulants in the 
year preceding the index date (the date of the first statin prescription). There was a total of 
4316 patients in the secondary prevention cohort and 13 642 patients in the primary 
prevention. Patients were followed until June 30th 2001. In the secondary prevention cohort, 
persistence was 71 % after 6 months of treatment and 45% after 3 years, while in the 
primary prevention cohort, the rates were 65% and 35%, respectively. Patients treated for 
primary prevention were also 18% less likely to be persistent compared with those in 
secondary prevention (HR=1.18; 95% CI 1.11-1.25). 
Another observational study using the administrative databases of Quebec was done 
in order to determine the persistence and adherence to cholesterollowering drugs.58 From a 
random sample of patients enrolled in the provincial drug reimbursement pro gram between 
J anuary 1 st and Oecember 31 st 2002, patients were included in the analysis if they had used 
a cholesterol lowering drug between J anaury 1 st 1999 and Oecember 31st 2000. Patients 
were excluded if they used any cholesterol lowering drug in the year preceding their use in 
1999 or 2000. The 2-year persistence and adherence of Il 838 users of statins was found to 
be 83% and 60%, respectively. 
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5.3 Determinants of adherence and persistence 
Discontinuation and poor adherence of statin therapy contribute to the failure of 
treatment targets. Therefore, studies have emerged in order to investigate risk factors of 
poor compliance. Greater adherence to statins is associated with the presence of CVD risk 
factors such as age, hypertensiop, diabetes or previous CAD events. 14, 59, 60 It is also 
positively associated with hospitalisations for CAD prior to statin initiation. In addition, 
men tend to have better adherence to their therapy than women. 14, 59, 60 
The Persistence and determinants of statin therapy among middle-aged patients for 
primary and secondary prevention study was performed using the RAMQ databases.57 As is 
the case with adherence, this study found that CVD risk factors such as age, male sex, 
hypertension and diabetes are associated with greater persistence. Furthermore, patients 
living in a rural environment as well as those who have been hospitalised have lower rates 
of cessation. However, patients in primary prevention along with patients who used the 
greatest number of pharmacies and physicians are less likely to be persistent. 
5.4 Impact of non adherence on morbidity 
The benefits of statins have been proven in clinical trials where the majority of 
patients are adherent to their treatment. From these trials, the expected reduction ih LDL 
cholesterol according to statin and dose has been computed. The expected reductions in 
LDL cholesterol vary between 22 and 60%.61 However, in clinical practice the observed 
reductions in LDL cholesterol are about 80% of those expected, which is a result of poor 
adherence.61 
The only study that evaluated the impact of statin non adherence on the rate of CVD 
in primary prevention was done using the RAMQ databases.62 The cohort was comprised of 
20543 patients aged 50 to 64 years without CVD and newly treated with statins. Adherence 
was defined as the percentage of doses used over a specified period and was categorised as 
2:90% or <90%. The authors did not find an association between adherence and nonfatal 
CAD. However, when stratifying for follow-up time, after one year of treatment adherent 
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patients (those with an adherence of at least 90%) were 19% less at risk of nonfatal CAD 
events (RR=0.81; 95% CI 0.67-0.97) compared with patients with an adherence lower than 
90%. The fact that adherence only had an effect on nonfatal CAD after one year of 
treatment can be explained by findings that statin effectiveness begins to be apparent after 1 
full year of treatment. 6. 7 
6. SOURCES OF BIAS IN PHARMACOEPIDEMIOLOGICAL STUDIES 
The role of pharmacoepidemiological studies is to investigate the utilization and 
effects of drugs already on the market in large groups of the population. Unlike RCTs, 
observational studies do not allow for identical study groups. Therefore, the effect 
measured cannot solely be attributed to the study treatment, unless appropriate adjustment 
is made on variables with unbalanced distribution between study groups. There are three 
categories of bias in observational studies: selection bias, information bias and 
confounding.63 . 64 
6.1 Selection bias 
Selection bias is related to the recruitment of study subjects or losses to follow-up. 
Therefore, the sample population chosen is not representative of the population at risk. In 
pharmacoepidemiology, there are four types of selection bias: referral bias, self-selection, 
prevalence study bias and protopathic bias. 
Referral bias occurs when the use of the drug contributes to the diagnostic process. 
The most common example is that of deep vein thrombosis diagnosis in women using oral 
contraceptives. When these women present themselves with leg pain, the fact of a well-
established association between the disease and oral contraceptive use makes them more 
likely to be subjected to diagnostic tests for deep vein thrombosis. This type of bias tends to 
overestimate the association between the drug and the disease. In adherence studies, this 
bias can be eliminated if aU cases are identified regardless of adherence levels. 
Self-selection occurs wh en patients decide themselves to participate or to leave a 
study. The patient's decision might be related ta drug exposure or to a change in health 
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status. It is therefore important to assess whether the patients who participate are similar to 
those who don't and whether those who leave are similar to those who remain in the study. 
However, adherence studies using administrative databases are not touched by this type of 
selection bias, since the patients do not have a sayon whether they participate or not. 
A prevalence study bias can occur in case-control studies when prevalent cases of 
the study outcome are selected instead of the incident cases. Since prevalence is 
proportional to incidence and duration of the disease and given that the latter is generally an 
indicator of disease prognosis, an association between drug exposure and prevalent cases 
can actually be an association with a prognostic factor rather than with incidence of the 
disease. In adherence studies, prevalence study bias can be greatly reduced by the use of 
administrative databases which allow investigators to go back in the records of the patients, 
as far back as a few years, so that they can select only the incident cases of the study 
outcome. 
The last type of selection bias, protopathic bias, occurs when a certain exposure is 
started, changed or stopped due to disease manifestation or a particular outcome. In 
consequence, there might be sorne confusion in determining the cause of the disease or of 
the outcome of interest. This bias occurs wh en prevalent cases are selected since diseases 
are generaUy identified late after the first clinical expression and it is difficult to assess past 
exposure as it can change over time. This type of bias is problematic in studies using 
administrative databases since these only contain information on the date of diagnosis of a 
disease and not on the date of symptom onset. However, this bias is less significant for 
acute events since the date of diagnosis and date of symptom onset are approximately the 
same. Furthermore, the use of administrative databases in adherence studies allow for the 
selection of incident cases and of patients who are incident users of the medication of 
interest, therefore greatly reducing protopathic bias. 
6.2 Information bias 
Information bias arises when there are errors in the measurement of exposure or 
outcome. Erroneous information is referred to as being misclassified. For example, if an 
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adherent patient is placed as non adherent, then a classification error has taken place. There 
are two types of misclassification, differential and nondifferential. 
A nondifferential misclassification occurs when the classification error is 
independent of the exposure-outcome relationship, Le. when it is random. This type of 
misclassification implies that the percentage of misclassified patients among cases and 
controls is equal and tends to dilute the effect or produces estimates that are close to the 
null value. If the misclassification is severe, the bias can also reverse the direction of 
association. In adherence studies using administrative databases, this type of bias can be 
introduced in the assessment of exposure (i.e. adherence), since databases only have 
information on medications dispensed to patients and there is no way of knowing whether 
patients actually take them or not. 
A differential misclassification occurs when the classification error is related to the 
exposure-outcome relationship. In a case-control study, it can occur when outcome status 
influences exposure determination, while in a cohort study it takes place wh en exposure 
status influences outcome identification. This type of misclassification can either 
underestimate or overestimate the exposure-outcome association. The two types of 
differential misclassification in pharmacoepidemiology are recall bias and detection bias. 
Recall bias is mostly frequent in retrospective and case-control studies. Cases tend 
to recall more accurately their past exposures th an controls. In this case, the bias can be 
controlled by choosing, if possible, a control group that is likely to have the same recall 
capacity as the cases. Another way to avoid this bias is to extract the information needed 
from medical records. Adherence studies can avoid this bias by using administrative 
databases to determine past exposure. 
Detection bias affects both cohort and case-control studies. It occurs when 
knowledge about exposure or outcome status influence follow-up procedures and exposure 
assessment in cohort and case-control studies, respectively. Adherence studies using 
administrative databases are not touched by this bias, since aIl patients are assessed in the 
same manner. 
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6.3 Confounding 
Confounding occurs when two or more factors are c10sely associated and the effect 
of one (or several) confuses or distorts the effects of the other factor(s) on the outcome. The 
distorting factor is called a confounding variable. A confounding variable must be 
associated with exposure as well as the outcome without being in the causal pathway 
between them. Hence, the confounder is an independent risk factor. A confounding variable 
can be responsible for a part or aIl of the association between exposure and outcome. It can 
also inflate, reduce or ev en reverse the association. Adherence studies can be greatly 
affected by confounding. However, this bias can be controIled in data analysis by 
stratification, multivariate analyses or subgroup analyses. 
The most important confounding factor in pharmacoepidemiology is confounding 
by indication since, in theory, there is always a reason for prescription and because the 
reason is usually associated with the outcome of interest. This phenomenon is due to the 
fact that patients who take a drug are generaIly different than those who don't due to the 
medical indication for which the drug was prescribed. In other words, even if the groups of 
patients compared have the same disease, there will be differences in disease severity or 
other risk factors between patients who receive different treatments. The problem of 
confounding by indication can be considered in the same perspective as selection bias, 
since the decision to prescribe can be viewed as one way to select a group of patients. If 
this selection process is also related to the outcome of interest, then there is a bias. This 
shows that for a given drug, the possibility of bias can be directly related to the outcome of 
interest and may change over time. This also shows the difficulty of adjusting for 
confounding by indication. In adherence studies, selecting patients that were aIl prescribed 
the same c1ass of drug can reduce the likelihood of this bias. 
In practice, it is often impossible to obtain an accurate estimate of the effect of this 
indication bias even wh en the reasons for prescribing seem straightforward. The reason for 
this is that indication is a complex and multifactorial phenomenon. Nonetheless, even if 
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confounding by indication is present in a study, the results obtained can be useful for other 
purposes. For example, if the association between a drug and outcome is confounded by 
disease severity, the fact that this drug was positively correlated with the outcome can be 
useful to physicians, since the amount of drug use becomes a good indicator of prognosis. 
METHODS 
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1. OBJECTIVES 
The main objective is to evaluate the impact of statin adherence on cerebrovascular 
disease among patients 45 to 85 years old without a history of cardiovascular disease and 
who initiated a new statin therapy between January 1999 and December 2004. 
1.1 Specifie objectives 
The specifie objectives are: 
1) To compare the impact of adherence levels «20% vs. 20-39%, 40-59%, 60-
79% and ~80%) on the incidence of cerebrovascular disease. 
2) To compare the impact of adherence levels (~80% vs. <20%) on the incidence 
of ischemic and hemorrhagic stroke, separately, as a subgroup analysis. 
1.2 Secondary objectives 
To identify the factors that are associated with an increased risk of cerebrovascular disease. 
To evaluate the impact of different levels of statin adherence on the rate of cerebrovascular 
disease. 
2. DATA SOURCE 
This observational study was done using the databases of the Régie de l'Assurance 
Maladie du Québec (RAMQ), govemment body responsible for the administration of the 
provincial health programs, and the hospital discharge summary database MED-ECHO 
(Maintenance et Exploitation des Données pour l'Étude de la Clientèle Hospitalière). 
The RAMQ database contains information from three types of files. The 
demographic data file contains the age, sex, year of death and postal code of everyone 
covered by the provincial health insurance plan. These beneficiaries are individuals on 
welfare, people over the age of 65 and starting from 1997, they also include individuals 
under the age of 65 who do not have access to private prescription drug insurance. The 
medical data file contains aIl the information relative to medical services received: nature, 
date and location of medical service (inpatient or ambulatory) as weIl as the diagnostic 
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codes which are identified according to the international classification of disease (lCD-9).65 
The procedure codes are also enclosed and are determined by the Canadian classification of 
diagnostic, therapeutic, and surgical procedures.66 The pharmaceutical file contains data 
concerning prescription medications that are dispensed from community pharmacies and 
reimbursed by the provincial prescription drug insurance plan. Therefore, it is possible to 
know the common denomination, the dose, the amount of medication given to the patient, 
the prescription period and the specialty of the prescribing physician. This data is received 
from the pharmacist who filled out the prescription. Moreover, this file also contains the 
start and end date of the prescription drug insurance coverage period of the patient. The 
first two files contain data on everyone covered by the provincial health insurance plan, 
therefore the entire Quebec population. Data from the pharmaceutical file are from 
beneficiaries of the provincial prescription drug insurance, which represent 45% of the 
Quebec population. These beneficiaries are individuals on welfare, people over the age of 
65 and starting from 1997, the y also include individuals under the age of 65 who do not 
have access to private prescription drug insurance. The three files are linked by the medical 
insurance numbers of the patients, which are encoded in order to preserve confidentiality. 
This database has been used in pharmacoepidemiological studies and certain files have 
been validated.67. 68 One study evaluated the accuracy of stroke diagnostic codes in 
administrative hospital dis charge data.69 Using the first 2 discharge diagnoses, ischemic 
stroke (lCD-9 codes 433, 434, and 436), was found to have a sensitivity of 80%, a 
specificity of 96%, and a positive predictive value of 91%; while for intracerebral 
hemorrhage (code 431), those values were 85%, 94%, and 83%, respectively.69 
The MED-ECHO database, on its behalf, contains information on hospitalizations. 
The diagnostic codes for hospitalizations are based on the international classification of 
disease (lCD-9).65 
3. COHORT DEFINITION 
The study population consisted of aIl drug plan members between 45 and 85 years 
of age without CVD who initiated a new therapy with statins (atorvastatin, rosuvastatin, 
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lovastatin, pravastatin, fluvastatin or simvastatin). Treatment had to be initiated between 
January 1st 1999 and December 31st 2004. The date of the first prescription was considered 
the cohort entry date. To be considered a new user of statins, the subject must not have 
received a hypolipidemic agent (statin, fibrate, resin or niacin) in the two years previous to 
the cohort entry date. Therefore, the subject must have been registered in the provincial 
prescription drug insurance plan at least 2 years before the cohort entry date in order to 
verify the absence of hypolipidemic agents in the pharmaceutical file. 
In order to have patients in primary prevention, subjects must not have previously 
had a cardiovascular disease. Therefore, there had to be an absence of diagnostic codes or 
medical procedures related to CVD in the five years preceding the cohort entry date. 
Furthermore, there had to be absence of medication linked to CVD in the pharmaceutical 
file 2 years before the cohort entry date. The latter was limited to 2 years since the 
provincial prescription drug insurance plan only started in 1997. However, smce the 
medical file contains information on aIl the Quebec population, irrespective of prescription 
drug insurance coverage, we have access to medical information over a longer period of 
time. We chose a 5-year period because we believe that it is reasonable to assume that a 
subject is free of CVD if he does not have its symptoms in the five years previous to 
initiating a statin treatment. 
Exclusion criteria for CVD: 
1) Exclusion of patients with coronary artery disease: myocardial infarction, angor or 
other forms of ischemic cardiopathies (lCD-9 codes 410-414) in the 5 years 
preceding the cohort entry; medical procedure such as the setting of a vascular 
endoprosthesis, angioplasty or stent in the 5 years preceding the cohort entry; use of 
nitrate vasodilators in the 2 years preceding the cohort entry. 
2) Exclusion of patients with cerebrovascular disease: diagnostic codes (lCD-9: 430-
438) in the 5 years preceding the cohort entry; medical procedures in the 5 years 
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preceding the cohort entry; use of nimodipine in the 2 years preceding the cohort 
entry. 
3) Exclusion of patients with heart failure: diagnostic code (lCD-9: 428) in the 5 years 
preceding the cohort entry; use of the following medication: furosemide alone or in 
combination with digoxine, angiotensin-converting enzyme inhibitors (ACEI), 
spironolactone, ~-blockers or carvedilol in the 2 years preceding cohort entry. 
4) Exclusion of patients with arrhythmias: diagnostic code (ICD-9: 427) in the 5 years 
preceding the cohort entry; medical procedures received using a stimulator or an 
electric fibrillator in the 5 years preceding the cohort entry; use of anti-arrhythmia 
medication (amiodarone, digoxine, quinidine, disopyramide, flecaidine, mexiletine, 
procainamide, propafenone or sotalol) in the 2 years preceding the cohort entry. 
5) Exclusion of patients with peripheral artery disease: diagnostic codes (ICD-9: 440-
447) in the 5 years preceding the cohort entry; medical procedure codes of non 
coronary revascularization in the 5 years preceding the cohort entry; use of 
pentoxifylline in the 2 years preceding the cohort entry. 
6) Exclusion of patients who received antiplatelet medication, or anticoagulants in the 
2 years preceding the cohort entry. 
The follow-up period began at the cohort entry date and ended when one of the 
following had occurred: cerebrovascular event, death, end of coverage by the provincial 
prescription drug insurance or end of the study period (June 31 st 2005). If a patient 
developed a CVD, he remained in the cohort as a potential case. However, the development 
of a CVD was taken into account as a potential confounder in the analysis. Only the first 
occurrence of cerebrovascular disease was analysed. The subjects could be followed for a 
minimum of 6 months and up to a maximum of 6.5 years. 
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4. STUDY DESIGN 
4.1 Nested case-control 
A nested case-control design was used in order to evaluate the risk of cerebrovascular 
disease in relation to adherence level. To do so, all subjects who had a cerebrovascular 
disease during the study period were identified. At the same moment, up to 15 controls 
were selected at random from the source population (cohort), who constituted all subjects at 
risk of developing the primary outcome. This is known as incidence density sampling and 
when used with a nested case-control design, the incidence density sampling technique 
allows the odds ratio tobe an unbiased estimate of the rate ratio.70 The controls had to have 
the same age at the cohort entry date and the same follow-up period as the cases. The 
probability of being a control was proportional to the time a subject contributed to the 
denominator of its rate (person-time of the cohort). A subject selected to be a control was 
always eligible to become a case and a control could be selected more than once. 
4.2 Justification of study design 
Adherence is defined by the percentage of doses of a medication that a patient takes 
compared to the doses he should be taking in a given period of time. Therefore, in order to 
compare statin adherence between patients, they must have identical follow-up periods. 
When studying an exposure that varies with time, such as adherence to statins, an 
additional level of complexity is introduced by the need to account for time-dependent 
exposure in the analysis; and this can be accompli shed by cohort analysis using Cox 
regression including time-dependent covariates. Altematively, a nested case-control 
approach can be used providing the exposure and covariates information for controls reflect 
values corresponding to the time of selection of their respective case. Nested case-control 
analyses have been found to yield results that were similar to results of Cox regression on 
the full cohort when studying time-dependent exposures, with the advantage of superior 
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computational efficiency with the conditional logis tic regression, given that only a sample 
of aIl possible controls are included in the risk set of each case.7I , 72 
5. PRIMARY AND SECONDARY ENDPOINTS 
The primary endpoint is a composite of intracerebral hemorrhage (ICD-9: 431), 
other and unspecified intracranial hemorrhage (432), occlusion and stenosis of precerebral 
arteries (433), occlusion cerebral arteries (434), acute cerebrovascular disease but ill-
defined cerebrovascular disease (436), and other and ill-defined cerebrovascular disease 
(437). 
The secondary endpoint is ischemic and hemorrhagic strokes, separately. These 
events were identified in the databases using the ICD-9 diagnostic codes.66 
6. EXPOSURE (INDEPENDENT VARIABLE) 
The exposure corresponds to the level of adherence to statin therapy as defined by 
the percentage of doses of a medication that a patient takes compared to the doses he 
should be taking in a given period of time. Adherence was measured using a medication 
possession ratio (MPR)56, which was obtained by ca1culating the percentage of days 
exposed to statins in a given foIlow-up period. Since a nested case-control design was used, 
this period corresponded to the difference between the cohort entry date and the index date 
(time at which a case had appeared or date of selection for controls). Adherence levels of 
patients were ca1culated at the time at which a case had appeared and for the controls 
selected at the same moment. The number of days exposed to statins was determined using 
renewal dates while taking into account the prescription period. 
An algorithm was created to ca1culate the adherence to statins. The latter used 
prescription dates, the amount of medication dispensed to the patient as weIl as the 
prescription period. The type or dose of statin prescribed was not considered when 
ca1culating adherence, since the interest was in the adherence to the class of statins. Thus, if 
a patient were to change the type of statin taken of if the dose was modified, this was not 
taken into consideration in the ca1culation of adherence nor in the analysis. 
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Those exposed to at least 80% of the doses were defined as adherent patients, while 
those exposed to less than 80% were defined as non-adherent. The cut-off point was chosen 
according to the literature on adherence. 14. 38. 73. 74 
7. CONFOUNDING FACTORS 
There are multiple cardiovascular risk factors. Therefore, it was essential to adjust 
the analyses for certain variables that could increase risk. AIl the analyses took into account 
the age and the sex of the patients, as identified at the cohort entry date. Since the databases 
do not contain any information on the annual salary of the patients, the socio-economic 
status was estimated by the type of drug reimbursement plan that the patient had. Diabetes 
was identified using the ICD-9 diagnostic code (250) or the use of hypoglycaemic 
medication one year before the cohort entry date and during follow-up. Hypertension was 
identified using the ICD-9 diagnostic code (401) or the use of anti-hypertensive medication 
one year before the cohort entry date and during follow-up. Patients with hypertension or 
diabetes diagnosed in the year preceding the index date were considered as newly 
diagnosed with hypertension or diabetes mellitus. For the other patients, the use of 
antihypertensive or antidiabetic agents in the year before the index date were dichotomised 
into two levels: adherence to more than 80% of the prescribed doses and non adherence to 
less than 80%. Patients who were diagnosed with diabetes mellitus or hypertension but 
never treated were defined as such. The number of co-morbidities in the year prior to the 
cohort entry date and during the follow-up period were taken into account using a modified 
chronic disease score (CDS)75 «4 vs 2:4). The CDS is a comorbidity metric that uses drugs 
dispensed as surrogate markers for chronic illness instead of using clinical diagnoses. 
Scores are weighted according to the number of different chronic diseases under treatment. 
8. DATA ANALYSIS 
The first part of the analysis was on the descriptive statistics of the study 
population. Demographic and clinical data was compared between cases and controls. 
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Means and frequencies were ca1culated for continuous and categorical variables and were 
analysed using t-tests and X2 tests, respectively. 
A conditional logis tic regression model was used to evaluate the rate ratios of 
cerebrovascular disease as a function of statin adherence, while adjusting for the 
confounding factors described previously. 
Sensitivity analyses were performed in order to verify the robustness of the results. 
For the first analysis, various categories of adherence (20-39%, 40-59%, 60-79%, 2:80%) 
were compared to an adherence of <20% in order to assess the effect of different adherence 
levels on cerebrovascular disease. The second analysis was performed to assess the 
robustness of our results regarding potential biases due to unmeasured confounders. It was 
done using the Greenland approach, which considers that an unmeasured risk factor is less 
frequent among adherent than non adherent patients.76 
AU the analyses used a precision threshold of 5% and were done using SAS version 
9.1 (SAS Institute, Cary, North Carolina, USA). 
9. SAMPLE SIZE CALCULATION 
The required sample size is ca1culated based on the incidence of the event studied in 
the unexposed group. However, there is no data in the literature on the incidence of 
cerebrovascular disease in nonadherent patients. It is therefore necessary to find an 
approximated incidence of cerebrovascular disease using different resources, such as the 
annual incidence of stroke in the general population and the incidence found in clinical 
trials evaluating the efficacy of statins in primary prevention. 
This is of course a cru de estimate since it is quite possible that the rate of 
cerebrovascular disease in these populations is not equivalent to the one of nonadherent 
patients. This said, the sample size ca1culated is only an approximation and it is only used 
as a guide in the preparation of the study. 
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Estimation of the incidence based on the general population 
According to the Heart and Stroke Foundation of Canada, the hospitalization rate 
for ail stroke in 2000/2001 was 5902 per 100000, or 5.9%, for men and women aged 40 to 
89 years. l 
Estimation of the incidence based on clinical trials 
The incidence of cerebrovascular disease can also be estimated using the incidence 
in the placebo group in clinical trials of primary prevention. However, no primary 
prevention trial has reported the rate of stroke. The sample size was therefore estimated 
using data from the Baigent et aL meta-analysis.' This study included data from primary 
and secondary prevention trials and the rate of stroke in the control group was found to be 
3.7%, whereas in the treatment group it was 3.0%. 
Determining the minimal risk reduction to be detected 
The sample size calculation was based on a 25% risk reduction of cerebrovascular 
disease, which was found in two meta-analyses.47,49 Different sample size estimates were 
made by varying the risk reduction and incidence of disease, while keeping the precision 
and power at 95% and 80%, respectively. (Table II) 
Sample size 
Estimating a risk reduction of 25% and an incidence rate of 4%, about 3200 cases 
wou Id be·required. Given that the cohort of primary prevention patients aged 45 to 85 years 
was estimated to include around 150000 patients, it was believed that the cohort would 
allow for a sufficient sample size. 
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Abstract 
Background: Clinical trials have demonstrated that statins can reduce cerebrovascular 
events including ischemic stroke. Observational studies have reported that after one year of 
treatment, only 40% of patients take at least 80% of their prescribed medication and that a 
third of patients stop their therapy. 
Objective: The aim of this study was to evaluate the impact of statin adherence on the rate 
of cerebrovascular disease (CD) among patients in the primary prevention setting. 
Methods: A cohort of 112092 patients was reconstructed using the RAMQ and Med-Echo 
databases. AlI patients without cardiovascular disease aged 45 to 85 years old who were 
newly treated with statins between 1999 and 2004 were eligible. A nested case-control 
design was used to study the occurrence of CD. Every case was matched for age and 
folIow-up period with up to 15 controls. Adherence level was reported as a medication 
possession ratio (MPR). Conditional logis tic regression models were used to estimate the 
rate ratio (RR) of CD adjusting for several covariables. 
ResuIts: The mean patient age was 63 years, 49% had hypertension, 21 % had diabetes, and 
41 % were males. A high level of adherence to a statin regimen was associated with 
reduction of CD (RR: 0.75; 0.67-0.85). Risk factors for CD were male gender, being a 
welfare recipient, hypertension, diabetes, higher chronic disease score and the development 
of cardiovascular diseases during folIow-up. 
Conclusions: Our study indicates that an adherence of 2:80% for more than 1 year is 
necessary to reduce the occurrence of CD. 
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Introduction 
Stroke is one of the leading causes of death in North America and it is also a leading cause 
of permanent disability.( l ,2) Stroke is also the second largest contributor to hospital care 
costs for cardiovascular disease (CVD).(2) Age, sex, smoking, hypertension and diabetes 
are well-established risk factors for stroke.(l) In addition, dyslipidemia is another well-
documented and modifiable risk factor for stroke that is attributable for 15% of ischemic 
strokes in the population.(l) 
Statins reduce the risk of stroke among patient with coronary artery disease (CAD) 
and those at increased risk for cardiovascular disease, although their effect in patients 
without CAD has not yet been weIl established.e -9) In the first primary prevention trial, 
WOSCOPS, only a smaU number of patients had diabetes or hypertension and no 
significant effect of pravastatin on stroke was found.(8) The AFCAPSlTexCAPS trial, 
which randomised patients without CVD, did not present any data on stroke.(9) Lastly, 
amongst the elderly patients without CVD in the PROSPER trial, statins had no effect on 
stroke occurrence.(7) However, the latest primary prevention trials, ASCOT-LLA, which 
included hypertensive patients and CARDS, which included patients with type 2 diabetes, 
found that atorvastatin significantly reduced the risk of stroke by 27% and 48%, 
respectively.(5,6) In addition, a few meta-analyses have demonstrated that statins can 
reduce the risk of stroke in primary prevention by 14-23%.(10,11) Moreover, a recent 
clinical trial found that statins reduced the risk of ischemic stroke, but increased the risk of 
hemorrhagic stroke.(12) Two additional trials also reported that the protective effects on 
stroke occurrence were only significant by the second year oftreatment.(13,14) 
Despite these results, the use of statins in real-life is suboptimal. Indeed, after one 
year of treatment, only 40% of patients are adherent to their statin therapy (i.e. take al least 
80% of their prescribed dose) and only 65% of patients continue their therapy.(l5,16) Non 
adherence is Iikely an important source of preventable cerebrovascular morbidity and 
mortality. Unfortunately, litde data is available on this topic. The purpose of this study is to 
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evaluate the impact of statin adherence on the rate of CD among patients 45-85 years of age 
in the primary prevention setting. 
Methods 
Data Sources 
This observational study was done using the databases of Med-Echo and the Régie de 
l'Assurance Maladie du Québec (RAMQ), which administers the Quebec health insurance 
as weB as the public prescription drug insurance plans. The Med-Echo database contains 
data on acute care hospitalizations, such as date of admission, length of stay as well as 
primary and secondary diagnoses. The RAMQ database contains information from three 
types of files. The demographic data file contains the age, sex, year of death and postal 
code for a11 registered individuals. The medical data file contains a1l the information 
relative to medical services received: nature, date and location of medical service (inpatient 
or ambulatory) as weIl as the diagnostic codes, which are identified according to the 
international classification of disease (lCD-9).(17) The procedure codes are also enc10sed 
and are determined by the Canadian classification of diagnostic, therapeutic, and surgical 
procedures.(18) These procedure codes are carefully audited.(19) The prescription claims 
file contains data on prescription medications that are dispensed to patients insured by the 
RAMQ and include common denomination, dose, amount of medication given to the 
patient, prescription period and specialty of the prescribing physician. 
The first two files contain data on everyone covered by the provincial health 
insurance plan, that is to say the entire Quebec population. Data from the prescription 
c1aims file are from beneficiaries of the provincial prescription drug insurance, which 
represents about 40% of the Quebec population aged 45-64 years, and about 94% of those 
65 years and 0Ider.(20) The three files are linked by the medical insurance number of 
patients. The prescription claims database .has been used in pharmacoepidemiological 
studies and is an accurate mean of determining drugs dispensed to individuals.(21) Other 
studies have assessed the validity of administrative hospital discharge data.(22) For 
ischemic stroke (lCD-9 codes 433, 434, and 436), the sensitivity was 80%, specifi ci ty was 
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96%, and positive predictive value was 91%, using the first 2 discharge diagnoses; for 
intracerebral hemorrhage (code 431), those values were 85%, 94%, and 83%, 
respectively.(22) 
Of the 3962 CD cases identified in our study, 67% were ischemic strokes, 7% were 
intracerebral hemorrhage and 17% were classified as other and ill-defined cerebrovascular 
disease. 
Cohort Study 
Using the RAMQ databases, we constructed a cohort of patients who initiated a statin 
treatment (atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin or simvastatin) 
between January 1st, 1999 and December 31st, 2004. The date of the first statin 
prescription was defined as the cohort entry date, and these patients did not take any lipid-
lowering drugs in the two years preceding their cohort entry. Patients had to be 45 to 85 
years old at cohort entry and had to be covered by the public prescription drug insurance 
plan for al least two years prior to cohort entry. 
To be eligible, subjects cou Id not have any indication of CVD as 
evidenced by the absence of a diagnosis or medical procedure in the last 5 years, and 
any drug marker in the 2 year before the cohort entry date. Patients had to be free of 
any marker of CVD such as A) CAD: myocardial infarction (MI), angor or other forms 
of ischemic cardiopathies (ICD-9: 410-414); medical procedure such as the setting of a 
vascular endoprosthesis, angioplasty or stent; use of nitrate vasodilators; B) 
cerebrovascular disease: diagnostic codes (ICD-9: 430-438); use of nimodipine; C) 
heart failure: diagl)ostic code (ICD-9: 428); use of furosemide alone or in combination 
with digoxine, angiotensin-converting enzyme inhibitors (ACEI), spironolactone, ~­
blockers or carvedilol; D) arrhythmias: diagnostic code (ICD-9: 427); medical 
procedures received using a stimulator or an electric fibrillator; use of anti-arrhythmia 
medication (amiodarone, digoxine, quinidine, disopyramide, flecaidine, mexiletine, 
procainamide, propafenone or sotalol); E) peripheral artery disease (PAD): diagnostic 
codes (ICD-9: 440-447); medical procedure codes of non coronary revascularization; 
use of pentoxifylIine. The RAMQ drug database also was used to exclude patients who 
received other drugs such as antiplatelets (excluding low dose of aspirine), or 
anticoagulants during the two years preceding the cohort entry. 
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The study cohort included 112092 patients who were folIowed from cohort entry 
until their first CD event or until the end of the study period (June 30th, 2005). Patients 
were censored during folIow-up wh en one of the folIowing had occurred: death, end of 
coverage by the RAMQ drug insurance plan or a prescription for another class of lipid-
lowering drugs (e.g. fibrates, etc). Subjects could be folIowed for a minimum of 6 months 
and up to a maximum of 6.5 years. AlI cardiovascular events including CD and alI-cause 
mortality rates were assessed in the cohort. CVD death was defined as death within 30 
days of hospitalization for CVD, while death from CD was defined as death within 30 
days of hospitalization for CD. 
Nested Case-Control 
A nested case-control design was used to estimate the rate ratio (RR) of CD in relation to 
statin adherence level. CD event was defined as a composite endpoint of: intracerebral 
hemorrhage (lCD-9 431), other and unspecified intracranial hemorrhage (432), occlusion 
and stenosis of precerebral arteries (433), occlusion of cerebral arteries (434), acute 
cerebrovascular disease but iII-defined cerebrovascular disease (436), and other and iII-
defined cerebrovascular disease (437). 
AH cases of CD were identified and up to 15 controls were selected at random from the 
source population (cohort) using density sampling. Since in this type of sampling each 
control is selected in proportion to his time contribution to the cohort, an unbiased RR is 
obtained.(23,24) The controls had the same age at the cohort entry date and the same 
folIow-up period as the cases. A subject selected to be a control was al ways eligible to 
become a case and a control could be selected more than once. 
Exposure Assessment 
For both cases and controls, adherence was measured using a medication possession ratio 
(MPR)(25), which was obtained by ca1culating the percentage of days exposed to statins in 
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a given foIlow-up period. The MPR was calculated using prescription dates, the amount of 
medication dispensed to the patient as weIl as the prescription period. Adherence for cases 
was calculated from the cohort entry date to the date of a CD event, while for the controls it 
was from the cohort entry date to the date of selection. The date of CD for the cases and the 
date of selection for the controls were defined as the index date. MPR was evaluated as a 
categorical variable, i.e. <20% (reference group), 20-39%, 40-59%, 60-79% and 2:80%. 
Based on literature data, equivalent in lowering LDL-cholesterol levels was estimated by 
using an equivalent dose of simvastatin. (26,27,28) 
Covariables 
Sex and social assistance were identified at cohort entry. The occurrence of CAD, CHF, 
P AD or other CVD events was assessed during follow-up. Diabetes and hypertension were 
identified in the year prior to entry in the cohort and during foIlow-up by ICD-9 code or 
drug markers. Patients with diabetes or hypertension diagnosed in the year preceding the 
index date were considered newly diagnosed. As for the other patients, the use of 
antidiabetic or antihypertensive agents in the year prior to the index date was dichotomised 
into two levels: high adherence indicated by having filled at least 80% or more of the 
prescribed doses and low adherence <80%. Patients who were diagnosed with diabetes 
mellitus or hypertension but never treated were defined as such. The reference categories 
were subjects with no hypertension and subjects with no diabetes, respectively. 
Dichotomised variables were also defined for the use of antiplatelet drugs (including ASA 
in daily doses inferior to 650mg). FinaIly, a modified patient's chronic disease score (CDS) 
was calculated in the year preceding the index date. The CDS is a comorbidity metric that 
uses drugs dispensed as surrogate markers for chronic illness instead of using clinical 
diagnoses.(29) Scores are weighted according to the number of different chronic diseases 
under treatment.(29) The CDS was dichotomized into two levels: CDS 2:4 or CDS <4. 
Statistical Analysis 
Baseline characteristics were compared using the t test for continuous variables and the X2 
test for categorical variables. A conditional logis tic regression model was used to evaluate 
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the rate ratios of CD as a function of statin adherence. The possible effect of time was taken 
into account by stratifying the analysis by the time of case occurrence (cases occurring in 
the first year of follow-up and those after one year of follow-up). Subgroup analyses by 
type of stroke (ischemic or hemorrhagic), by age group as weil as among patients having 
hypertension or diabetes and those without hypertension and diabetes were done. 
A sensitivity analysis with the exclusion of other and ill-defined cerebrovascular 
disease (lCD-9 437) was done to assess its impact on the RR. To assess the robustness of 
our results regarding potential biases due to unmeasured confounders, we used the Monte 
Carlo method proposed by Greenland and Steenland, which considers that an unmeasured 
risk factor is less frequent among adherent than non-adherent patients.(30,31) This type of 
analysis was performed because one limitation of these administrative databases is that the y 
do not conta in information on potential confounders such as smoking. Different scenarios 
were developed in which we changed the odds ratio (OR) between the unmeasured 
confounder and CD as weil as changing the prevalence of this confounder amongst 
adherent and non-adherent patients. The odds ratios and prevalence of confounders were 
taken from the literature and surveys. This allowed us to determine how the RR would 
change when adjusted for the unmeasured confounders. 
Ali the analyses used a precision threshold of 5% and were done using SAS version 
9.1 (SAS Institute, Cary, North Carolina, USA). 
Ethical Considerations 
No patient or physician could be identified due to the scrambled identification numbers that 
'were used throughout the study. The University of Montreal's Research and Ethics 
Committee approved this study. 
Results 
Characteristics of Patients 
The distribution of inclusion and exclusion criteria is shown in Figure 1. Of the 112092 
patients, most were prescribed either atorvastatin, simvastatin or pravastatin (Table 1). The 
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mean age of the patients was 63 years (SD ±1O) and the mean foIlow-up time was 2.95 
years. 
Baseline demographic characteristics were comparable across the statin groups. In the 
cohort, 41 % of patients were men, 16% were welfare recipients, 26% had diabetes and 54% 
had hypertension. Among the 112092 patients in the cohort, 3.5% had a CD (1.2 per 100 
person-years), 12.5% had a CAD event (4.2 per 100 person-years), 4.0% had CHF (104 per 
100 person-years), 3.6% had a PAD (1.2 per 100 person-years), 10.6% had another CVD 
diagnosis (3.6 per 100 person-years) and 32.9% took antiplatelet drugs (11.1 per 100 
person-years) without any diagnosed CVD. The percentages of CD mortality, CVD 
mortality and aIl cause mortality were 0.1 %,0.4% and 2.9%, respectively. 
The proportion of men, welfare recipients, patients with diabetes or hypertension, 
patients who developed a CVD diagnosis during follow-up, and patients with a higher 
chronic disease score was statistically higher among cases (Table 2). 
Impact of Adherence on CD and Risk of CD 
Multivariate analysis revealed that the benefits of statins on CD rate are only apparent after 
at least one year of foIlow-up. An adherence of 2:80% reduced the RR of CD by 25% 
(RR=0.75, 0.67-0.85) compared to an adherence <20% (Table 3). Risk factors such as 
diabetes and hypertension can increase CD incidence by 18% to 83%. The adjusted model 
showed that men (RR=1.24, 1.14-1.35) and welfare recipients (RR=1.30, 1.13-1.50) had a 
higher risk of developing a CD (Table 3). Developing CAD, CHF, PAD or other CVD 
during foIlow-up increased the risk of CD by 1.05 to 2.95 times. However, during the first 
year offollow-up, CAD, CHF, PAD and other CVD increased the risk of CD by 1.48,2.28, 
7.32 and 2.78, respectively. Developing 2 or more CVD during follow-up increased the risk 
of CD by 3.97 times during the first year of follow-up and this risk decreased to 2.43 after 
one year of follow-up. Finally, higher chronic disease score level (2:4) was associated with 
a higher CD occurrence (RR=1.46, 1.33-1.60). 
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Subgroups Analysis 
A subgroup analysis by the type of CD revealed that an adherence of ~80% reduced the RR 
of ischemic stroke (RR=0.67, 0.58-0.77), while no difference was seen for hemoIThagic 
stroke (RR=0.97, 0.59-1.58). Subgroup analysis by age showed that the risk reduction for 
CD was non significant for patients younger than 65 years (RR=0.80, 0.65-1.00), while a 
significant 28% reduction was found for patients 65 years and older (RR=0.72, 0.63-0.84). 
Among high-risk patients, i.e. those with hypertension or diabetes, an adherence of ~80% 
reduced the risk of CD by 29% (RR=0.71, 0.60-0.83), which is almost equivalent to the 
risk reduction found (RR=0.72, 0.58-0.89) for lower risk patients (those without 
hypertension or diabetes). 
Sensitivity Analyses 
As shown in Table 4, we considered that an unmeasured risk factor was less frequent 
among subjects with a high adherence level compared to those with a low adherence level. 
This analysis revealed that our conclusions might be overtumed when a confounder (ex. 
smoking) had an OR for CD of 3.0 or 4.0 for CUITent smokers and 2.0 for former smokers, 
in addition to a prevalence in the high adherence group of 15% smokers (8% CUITent and 
7% former smokers) as compared to 25% (18% CUITent and 7% former smokers) in the low 
adherence group (scenarios 5 and 6). As for the second sensitivity analysis, when other and 
ill-defined cerebrovascular disease (lCD-9437) was excluded from the outcome, we did 
not find a big change in the rate ratio (RR=0.77, 0.67-0.88). 
Discussion 
Our results indicate that higher adherence levels are associated with greater reductions in 
CD OCCUITence. The analyses revealed that an adherence of ~80% reduced the risk of CD 
by 25% (RR=0.75, 0.67-0.85) compared to an adherence of <20%. This result is similar to 
the 27% risk reduction found in the primary prevention ASCOT-LLA trial, and to the 23% 
risk reduction found in a meta-analysis of primary prevention studies.(5,1O) The decrease 
in CD risk found in our study is also comparable to the one reported in a recent meta-
analysis that examined the relationship of LDL cholesterol as a marker for stroke.(32) For a 
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1 mmol/L reduction in LDL cholesterol, aIl strokes were reduced by 17% (RR=0.83, 95% 
CI 0.78-0.88), ischemic stroke by 22% (RR=0.78, 99% CI 0.70--0.87) and there was no 
apparent effect on hemorrhagic stroke (RR=1.05, 99% CI 0.78-1.41).(30) Furthermore, our 
results are similar to the meta-analyses reporting the results of primary prevention trials. 
One of these meta-analyses found that the risk of stroke was reduced by 23% (RR=0.77 
95% CI 0.62-0.95) for patients without CAD, while there was no difference in hemorrhagic 
strokes (RR=1.03, 95% CI 0.49-2.16).(10) Another meta-analysis reported that statins 
reduced the risk of total strokes by 14% (RR= 0.86,95% CI 0.75-0.97).(11) 
The risk coefficients associated with diabetes, hypertension and prior cardiovascular 
disease are in line with those reported in the literature.(1,33) Previous studies found that 
patients with hypertension are at 1.4-4 times increased risk of stroke, while patients with 
diabetes have 1.8-6 times the risk.(1) Patients without clinical cardiovascular disease are at 
high risk of cardiovascular events on the basis of artherosclerosis disease in other vascular 
beds, and the presence of multiple risk factors. The association between the development of 
a CAD or PAD, and the fact of being at risk of cerebrovascular disease are in relation with 
literature data.(34) A previous CAD increases the risk of stroke by 1.2-2.1, whereas a 
previous diagnosis of PAD increases the risk of stroke by 2-4.(1,29) 
Our study design took into account the possibility of sorne methodological problems. 
To avoid selection bias, we used aIl incident statin users. In addition, given that the patients 
studied were aIl receiving statins, the likelihood of confounding by indication is reduced. 
However, we could not control for aIl patient characteristics that may influence the 
physician's choice. Unmeasured comorbidity as weIl as missing clinical data of cholesterol 
level could lead to residual confounding; yet there is no reason to believe that the 
prescribing of different statins would be strongly influenced by cholesterol values. The 
analysis of available baseline characteristics did not suggest preferential prescribing of a 
particular statin to sicker patients. 
We assessed the possibility that patients with comorbidities may have had more 
motivation to be adherent to prescribed statin drug regimens. As weIl, these patients may be 
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more likely to have a higher cardiovascular risk. We adjusted for several determinants with 
proxy comorbidity status such as diabetes, hypertension, and occurrence of CVD after the 
start of statin agents. Our multivariate analysis should have minimized the influence of 
confounding factors. Nevertheless, residual confounding effect due to incomplete or 
inaccurate measurement of covariates or unmeasured confounders cannot be excluded. 
The databases analyzed in this study do not contain information on the patients' 
cholesterol values before and after treatment. The current study had other limitations. 
First, databases do not allow adjustment for clinical severity. We thus did not have-and 
so cannot adjust for-cholesterol values before and after treatment. This shortcoming 
may be of minimal importance considering a recent study of patients with diabetes and 
dyslipidemia that reported that adherence to statin therapy is related closely to the 
attainment of the low-density lipoprotein goal and appears to increase substantially wh en 
adherence is greater than 80%.(35) To investigate the possible bias, we evaluated the rate 
of switching to other doses and found that most patients (84%) were taking the same, 
while the rate of switching to other statin was 9%. Second, in order to reduce the 
likelihood of confounding by dose, we adjusted for the equivalent simvastatin dose. The 
equivalent simvastatin doses were comparable among cases and controls. Third, we also 
could not adjust for blood pressure, the single most important modifiable risk factor for 
stroke. Indeed, the relative risk for stroke is approximately 4 times wh en hypertension is 
defined as systolic blood pressure 2:160 mm Hg and/or diastolic blood pressure 2: 95 mm 
Hg.(36) If patients were using medication to treat hypertension or diabetes, another well-
established risk factor for stroke, we considered their adherence to these drugs in the 
model adjustment. 
Death was also considered as an issue. For instance, most of the deaths in the study 
occurred relatively soon after a CVD events, and therefore we captured more likely cardiac 
related deaths. In addition, residual confounding by unmeasured factors is al ways possible. 
The RAMQ databases also do not contain any information about the patients' lifestyle. 
Therefore, it was not possible to adjust for smoking, obesity, lack of exercise and poor diet, 
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which are associated with stroke risk.(l) These factors may introduce a bias in our results 
since they are well-documented risk factors for stroke and they are more likely to be 
present among patients who are not adherent to their medication.(l, 37) Using the Monte 
Carlo sensitivity analysis, only the scenarios with the highest odds ratios between smoking 
and CD, (ie. 3.0 to 4.0) associated with a smoker prevalence of 15% in the high adherence 
group as compared to 25% in the low adherence group would invert the relationship 
between statin adherence and CD to a non significant level. This represents an unlikely 
scenario. 
Another limitation is that sorne patients included in our study may have had a 
previous cardiovascular disease event, which we could not identify in our databases. 
However, the probability of this misclassification is small since we had access to 
pharmaceutical and medical data for two and five years, respectively, prior to the cohort 
entry date. It is therefore reasonable to assume that our patients did not have symptomatic 
cardiovascular disease. In addition, since adherence was calculated using the prescription 
claims file, it is not possible to know wh ether or not patients took their medication. 
However, since patients paya portion of the drug's cost, they may be more likely to take il. 
Consequently, the possibility of bias is reduced. 
In spite of these limitations, we believe that our results are good estimates of the 
effect of statin adherence on CD occurrence in the primary prevention. In addition, 
administrative databases offer several advantages, such as the ability to provide a large 
study cohort and the capacity to reflect medication use in a real-world setting. Finally, this 
study population was large and representative of diverse sociodemographic characteristics. 
In summary, our results showed that an adherence level of 2:80% for a period of at 
least one year translates into a reduction of CD risk. Our study provides evidence to support 
statin use in primary CD prevention. 
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Figure 1: Flow chart of inclusion and exclusion criteria 
1 Exclusion criteria were assessed in the 2 years preceding cohort entry for medications and 
in the 5 years preceding cohort entry for hospitalisations, diagnoses, or medical procedures. 
Table 1. Characteristics of patients starting a new statin treatment in the RAMQ in 1999-2004 
Atorvastatin Fluvastatin Lovastatin Pravastatin Rosuvastatin Sirnvastatin 
No. Patients 70,968 2117 750 13,559 7,927 16,771 
Cerebrovascular events (no.) 2377 (3.3%) 107(5.1%) 31 (4.1%) 632 (4.7%) 100 (1.3%) 715 (4.3%) 
Mean age (continuous)* 63 (±1O) 63 (± 10) 63 (± 10) 64 (± 10) 63 (± 10) 64 (± 10) 
Mean dose (mg) 13 (± 6) 26 (±1O) 21 (± 6) 20 (±8) 11 (± 4) 18 (± 10) 
Simvastatin equivalence (mg) t 26 7 10 10 43 17 
Follow-up time (days) 1063 (± 601) 1531 (± 598) 1485 (± 649) 1324 (± 632) 430 (± 134) 1167 (± 596) 
Sex (% male) 42 35 35 37 46 41 
Social assistance (%) 16 18 19 15 14 14 
Diabetes mellitus (%)+ 27 20 19 24 26 19 
Hypertension (%)+ 54 52 47 53 57 56 
Antiplatelet use (%) 32 28 26 33 32 37 
Dose distribution (mg) (%)* 
5 1 0 0 0 1 6 
10 78 0 5 21 96 42 
20 
40 
80 
• At treatment initiation 
20 
1 
o 
60 
40 
o 
89 
6 
o 
71 
8 
o 
3 
1 
o 
43 
9 
o 
fStatins equivalence in simvastatin dose. Simvastatin lOmg = lovastatin 20mg = pravastatin 20mg = fluvastatin 40mg = atorvastatin 5mg = rosuvastatin 2,5mg 
+ICD-9 or pharmacologie treatment in the year before cohort entry 
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Table 2. Characteristics of patients with cerebravascular disease and matched contraIs 
Cases occurring in the tirst Cases occurring in the after 
year of follow-up and their 1 year of follow-up and their 
controls con trois 
p p 
Cases Controls value* Cases Controls value* 
Number 1366 20425 2593 38547 
Age (years) t 68 (±9) 68 (±9) 0.9842 67 (±9) 67 (±9) 0.7346 
Mean equivalent dose 
(mg)~ 23 (±13) 23 (±13) 0.1081 23 (±14) 22 (±13) 0.001 
Statin adherence (%)* 
<20% 4 5 0.2829 16 14 0.0159 
20-39% 6 6 0.9592 10 9 0.0417 
40-59% 7 6 0.1555 10 10 0.8302 
60-79% 9 9 0.7009 13 13 0.4412 
2:80% 74 75 0.5930 51 55 0.0005 
Sex (% male) 45 39 <0,0001 43 37 <0,0001 
Social assistance (%) 12 10 0.0033 14 11 <0,0001 
Diabetes (%) 31 30 0.0102 39 32 <0,0001 
Diagnosed and 
5 6 7 7 
untreated diabetes (%) Il 
Newly diagnosed (%)11 7 7 2 2 
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Antidiabetic agents 
5 4 10 6 
adherence <80% (%)'ll 
Antidiabetic agents 
14 13 20 17 
adherence .2:80% (%)'ll 
Hypertension (%) 71 59 80 70 
Oiagnosed and 
untreated hypertension 4 5 6 6 
(%)11 
Newly diagnosed (%)11 25 14 7 4 
Antihypertensive <0,0001 <0,0001 
agents adherence <80% 8 6 17 13 
(%)'lI 
Antihypertensive 
agents adherence <80% 35 34 50 47 
(%)'ll 
Having CAO during 
** 
4 2 
follow-up 
<0,0001 9 7 <0,0001 
Having CHF during 
follow-uptt 
1 0,4 <0,0001 3 2 <0,0001 
Having other CVO during 
follow-up** 
4 1 <0,0001 7 5 <0,0001 
Having PAD during 
follow-up§§ 5 1 <0,0001 
Having 2: 2 CVD events 
11 2 <0,0001 
during follow-up 
Use of antiplatelets 1111 15 12 0.0008 
Chronic disease score (% 
22 16 <0,0001 
2:4) 
'p values are related to analyses made to compare cases with controls 
t At treatment initiation 
60 
5 2 <0,0001 
26 11 <0,0001 
15 15 0.7952 
29 20 <0,0001 
t Statins equivalence in simvastatin dose. Simvastatin 10mg = lovastatin 20mg = pravastatin 20mg = 
fluvastatin 40mg = atorvastatin 5mg = rosuvastatin 2,5mg 
~Proportion of days covered (%) 
IIICD-9 or pharmacologie treatment; newly diagnosed diabetes or hypertension was detected in the year 
preceding the index date. 
<HProportion of days covered (%) in the year preceding the index date. 
"Diagnosis of CAD: MI or angina (lCD-9: 410-414), a medical procedure, i.e., coronary artery bypass 
grafting, angiography, or angioplasty, use of nitrate, including nitroglycerin. 
ttDiagnosis of CHF: diagnosis (lCD-9 428) or drug markers 
HDiagnosis of other CVD: arrhythmia (ICD-9 code 427), a medical procedure using a pacemaker or use of 
drugs for cardiac arrhythmias (amiodarone, digoxin, quinidine, disopyramide, flecainamide, mexiletine, 
procainamide, propafenone, or sotalol); or valvular heart disease; or anticoagulants. 
~~ Diagnosis of PAD: diagnosis (ICD-9 codes 440-447), medical procedure of noncoronary angioplasty, or use 
of pentoxifylline) 
1111 Antiplatelet users: use of dipyridamole, sulfinpyrazone, ticlopidine, dipyridamole+ AAS, clopidogrel, 
aspirin in doses ranging from 80 mg to 650 mg, and that without CAD, PAD,CHF or other CVD events. 
Table 3. Rate ratio (RR) of cerebrovascular disease 
RR(95% CI) 
Cases occurring in the tirst year Cases occurring after 1 year of 
of follow-up and their controls follow-up and their controls 
Crude Adjusted Crude Adjusted 
Statin adherence (%)* 
<20% Reference Reference Reference Reference 
20-39% 1,01 1,06 (0,74 - l,53) 0,99 0,97 (0,83 1,15) 
40-59% 1,17 1,24 (0,87 - 1,77) 0,87 0,83 (0,70 - 0,98) 
60-79% 1,05 1,09 (0,77 - l,53) 0,85 0,82 (0,71 - 0,96) 
2:80% 0,96 1,03 (0,76 - 1,38) 0,73 0,75 (0,67 0,85) 
Sex (male vs. female) 1,29 1,24 (1,10 - 1,39) 1,3 1,24 (1,14 - 1,35) 
Social assistance (yes vs. no) 1,39 1,30 (1,07 - l,6O) 1,49 1,30 (1,13 l,50) 
No diabetes Reference Reference Reference Reference 
Diagnosed and untreated diabetes t 0,9 0,81 (0,63 - l,OS) 1,03 1,04 (0,89 - 1,23) 
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Newly diagnosed diabetes t 1,06 0,87 (0,70 - 1,09) 1,11 1,02 (0,75 - 1,39) 
Antidiabetic drug adherence <80% tt 1,47 1,20 (0,92 - 1,56) 1,59 1,32 (1,14 - 1,54) 
Antidiabetic drug adherence 2:80% Tt 1,11 0,98 (0,83 - 1,17) 1,33 1,18 (1,06 - 1,31) 
No hypeltension Reference Reference Reference Reference 
Diagnosed and untreated hypertension t 0,95 1,28 (0,96 - 1,70) 0,91 1.35(1,12-1,64) 
Newly diagnosed hypertensiont 1,86 1,84 (1,56 - 2,15) 1,68 1,83 (1,52 - 2,20) 
Antihypertensive' agent adherence <80% tt 1,26 1,47 (1,17 - 1,86) 1,37 l,59 (1,39 - 1,83) 
Antihypertensive agent adherence 2:80% t* 0,96 1,22 (1,05 - 1,42) 1,15 1,33 (1,19 - 1,49) 
Having CAD during follow-up* 2,30 1,48 (1,08 - 2,04) 1,34 LOS (1,01 - 1,22) 
Having CHF during foUow-up Il 2,95 2,28 (1 ,27 - 4.09) 1,94 1,550,21-1,98) 
Having other CVD during follow-up'l! 3,44 2,78 (1,99 - 3,89) 1,62 1,54 (1,31 - 1,81) j 
j 
Having 2: 2 CVD events during follow-up 9,66 7,32 (5,30 - 10,10) 3,36 2,95 (2,41 - 3,59) j 
Having PAD during follow-up ** j 6,36 3,97 (3,13 - 5,03) 3,01 2,43 (2,18 - 2,71) 
Use of antiplatelets tt 1,25 (1,10 - 1,41) 
j 
1,32 1,61 (1,36 - 1,90) 0,99 j 
j 
j 
j 
j 
j 
Chronic disease score (2:4 vs. <4) 1,45 1,33 (1,15 - 1,53) 1,64 
'Proportion of days covered (%) 
t ICD-9 or pharmacologie treatment; newly diagnosed diabetes or hypertension was detected in the year preceding the index date. 
tProportion of days covered (%) in the year preceding the index date. 
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1,46 (1,33 1,60) 
*Diagnosis of CAD: MI or angina (ICD-9:410-414), a medical procedure, Le., coronary artery bypass grafting, angiography, or angioplasty, use of nitrate, including 
nitroglycerin. 
IIDiagnosis of CHF: diagnosis (ICD-9: 428) or drug markers 
'lIDiagnosis of other CVD such as arrhythmia: diagnosis (ICD-9: 427), a medical procedure using a pacemaker and the use of drugs for cardiac arrhythmias arrhythmias 
(amiodarone, digoxin, quinidine, disopyramide, flecainamide, mexiletine, procainamide, propafenone, or sotalol); or patients who received anticoagulants. 
* *Diagnosis of P AD: diagnosis (ICD-9 codes 440-447), medical procedure of noncoronary angioplasty, or use of pentoxifylline) 
if Antiplatelet users: use of dipyridamole, sulfinpyrazone, ticlopidine, dipyridarnole+ AAS, clopidogrel, aspirin in doses ranging from 80 mg to 650 mg, and that without 
CAD, P AD,CHF or other CVD events. 
Table 4: Change in RR of Cerebrovascular Disease after Adjustment for Unmeasured Confounders 
Prevalence of risk factor'll OR* (95% CI) Estimated RR (95% CI) of CD 
(high risk; medium risk) t 
High adherence Low adherence group High riskt Medium riskt 
group 
Scenarios 1 15% (8%; 7%) 19% (12%; 7%) 1.8 (1.2-2.3) 1.3 (1.1-1.8) 
Scenarios 2 15% (8%; 7%) 19% (12%; 7%) 2.5 (1.6-3.5) 2.0 (1.2-3.0) 
Scenarios 3 15% (8%; 7%) 25% (12%; 13%) 1.8 (1.2-2.3) 1.3 (1.1-1.8) 
Scenarios 4 15% (8%; 7%) 25% (18%; 7%) 3.0 (1.2-4.0) 2.0 (1.1-3.0) 
Scenarios 5 15% (8%; 7%) 25% (18%; 7%) 4.0 (1.2-5.0) 2.0 (1.1-3.0) 
• Risk factor between the confounder and CD; 
t High risk; medium risk are defined as smokers (cuITent smokers or former smokers) or obesity (severe or moderated); 
'1 Proportion at high risk and medium risk among high adherence and low adherence groups. 
0.77 (0.69-0.87) 
0.79 (0.70-0.89) 
0.79 (0.70-0.89) 
0.87 (0.75-1.04) 
0.92 (0.77-1.12) 
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DISCUSSION 
Primary prevention trials and meta-analyses have shown that statins can reduce 
stroke risk in primary prevention.9. Il, 47, 48 However, as discussed earlier, no data is 
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available on the effectiveness of statins in real life. It was therefore necessary to perform a 
population-based study in order to determine if we can ob tain the same results found in 
clinical trials in a situation of real-life clinical practice. Our study laid emphasis on three 
aspects of the effectiveness of statins in real-life practice: the minimal adherence necessary 
to have significant results, the impact on high-risk and low-risk individuals and the length 
of time required to ob tain benefits from treatment. 
First of all, we can see that greater adherence translates into greater cerebrovascular 
disease risk reduction. This trend lets us believe that it would be beneficial to promote 
adherence to treatment. Neuroprotection by statins is attributable to multiple mechanisms.77 
As a matter of fact, statins increase nitric oxide bioavailability, which regulates cerebral 
perfusion as well as improves endothelial function. Statins also stabilise atherosclerotic 
plaques and they have antioxidant, anti-inflammatory and anti-thrombotic properties.77 For 
patients followed for more than a year, cerebrovascular disease is reduced by 25% in 
patients taking at least 80% of their medication compared to patients taking less than 20% 
(RR=0.75, 0.67-0.85). This rate ratio is similar to the ones found in the ASCOT-LLA trial 
and meta-analyses.5. 9. 47, 48 Indeed, statins provided a 27% risk reduction in stroke in the 
ASCOT-LLA trial; white one meta-analysis found that for a 1 mmollL reduction in LDL 
cholesterol, all stroke was reduced by 17% (RR=0.83, 95% CI 0.78-D.88).5 Furthermore, 
one meta-analysis of primary prevention patients found that the risk of stroke was reduced 
by 23% (RR=0.77 95% CI 0.62-0.95), while another one found that statins reduced the risk 
of fatal and nonfatal strokes by 14% (RR= 0.86,95% CI 0.75_0.97).47,48 
In addition, we also determined the impact of statins on cerebrovascular disease risk 
in low-risk as well as high-risk patients. We found that among patients with hypertension 
or diabetes (i.e. high-risk patients), an adherence of 2:80% reduced the risk of 
cerebrovascular disease by by 29% (RR=0.71, 0.60-0.83). Similar results were found for 
those without hypertension or diabetes (i.e. low-risk patients). When we compare our 
results to the ones of the primary prevention trials ASCOT-LLA and CARDS, we see that 
the risk reductions in cerebrovascular disease found in the context of real-life practice are 
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lower than the ones obtained in clinical trials.9, Il The first trial found that atorvastatin 
reduced fatal and nonfatal strokes of aIl kinds by 27% (HR=0.73, 95% CI 0.56-0.96), while 
the second trial found that atorvastatin reduced stroke by 48% (HR=0.52, 95% CI 0.31-
0.89).9, Il Our smaller reductions in cerebrovascular events can be explained by several 
hypotheses. Firstly, our reference group was not patients taking a placebo, but rather 
patients with poor adherence to statins. Second, our patients were at lower risk than those 
of ASCOT -LLA and CARDS. The ASCOT -LLA trial included only hypertensive patients 
with at least three other cardiovascular risk factors, while CARDS was composed of 
diabetic patients who were CUITent smokers or who had at least one of the following: 
retinopathy, albuminuria, or hypertension.9. Il 
AIso, we found that at least one year of exposure to statins is required in order to 
obtain benefits in terms of cerebrovascular disease risk reduction. The impact of adherence 
to statins was only statistically significant in patients having taken their treatment for at 
least one year. We can therefore say that exposure time modifies the effects of statin 
adherence on the risk of cerebrovascular disease. The risk reduction is significant in 
patients having used a statin for over a year, but not in the first year of treatment. Although 
adherence is greater to 80%, statins show no reduction in cerebrovascular disease if they 
are used for less than one year. These results follow those of a primary prevention trial, 
which found that risk reductions for stroke were constant throughout the study though 
significant benefits were only evident at 2-year follow-up.45 
Lastly, we found that the risk coefficients associated with diabetes, hypertension 
and prior CVD are in line with those reported in the literature.25 , 78 We found that diabetes 
increased the risk of cerebrovascular events by 1.18-1.32 times, while hypertension 
increased the risk by 1.35-1.83 times. Previous studies have found that patients with 
diabetes are at 1.8-6 times at increased risk of stroke while hypertensive patients are at 1.4-
4 times the risk.78 We also found that having a CAD during follow-up increased the risk of 
cerebrovascular events by 1.05 times, which is close to the 1.2-2.1 increase in stroke risk 
due to CAD found in the literature.78 Additionally, having a PAD increases the risk of 
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cerebrovascular disease by 2.95 times, which is comparable to other studies that have found 
that a previous diagnosis of P AD increases the risk of stroke by 2-4 times.25 
Strengths and Limitations 
Internai Validity 
There are several advantages to using administrative databases in population-based 
studies. One of these advantages is that they allow for a large sample size at a low cost. 
However, since the distribution of treatment is not done at random, certain biases can be 
introduced. 
The first possible type of bias is selection bias. To avoid it, we used aIl incident 
statin users between 1999 and 2004. In addition, since aIl patients aged 45 to 85 years 
covered by the Quebec drug insurance plan can be included in the study, biases related to 
patient recruitment and loss of foIlow-up are eliminated. As for reference bias, which is 
introduced when the outcome is preferentially identified in one of the adherence categories, 
it does not affect the validity of our results. Indeed, since the outcome measured is very 
symptomatic, it is detected regardless of the patient's adherence level. 
Information bias is linked 10 the way with which the exposure, outcome and 
covariables are measured during the study. When an error is introduced in outcome 
detection independently of exposure, the strength of association between exposure and 
outcome is reduced, but it is not invalidated. The same is true for an error in exposure 
assessment that is independent of the outcome. On the other hand, if an error is introduced 
preferentially in one exposure group or in one outcome group, it is impossible to determine 
if the association found is overestimated or underestimated. This is known as differential 
misclassification error and it invalidates the association found between exposure and 
outcome. Information biases could have been introduced in certain aspects of our study and 
could have swayed our results in various ways. 
Firstly, a misclassification error could be possible in the assessment of exposure, 
which in our case is adherence level. Statin adherence was determined using the 
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pharmaceutical file of the RAMQ, which informs us on medications dispensed to patients 
by pharmacists. However, we cannot know from this database whether the patients actually 
took their medication. Since this misdassification error is not related to whether the patient 
is a case or a control, it is a non differential misdassification error and does not invalidate 
our results. This information bias can only underestimate the protective effect of a good 
adherence on cerebrovascular events. The sensitivity and specificity of the pharmaceutieal 
file of the RAMQ database in the detection of the true adherence of patients have never 
been evaluated. However, one study assessed the validity of cumulative medication 
acquisition ca1culated from the Manitoba prescription daims database against pill count 
medieation adherence.79 To do so, a sample of 32 community pharmacies in the Winnipeg 
area were approached. One or more pharmacists from each pharmacy were asked to recruit 
10 eligible patients. To be eligible, patients had to be at least 65 years of age, 
noninstitutionalised, taking 2 or more prescribed medieations (that were not creams, oral 
liquids, ophtalmies, inhalers or other non oral dosage forms) on a daily basis, taking an 
angiotensin-converting enzyme inhibitor and willing to provide signed informed consent. 
Pill counts were performed on aIl prescribed medications during 3 home interviews over 
the course of 4 months and 10 months of prescdption daims data were collected on each 
patient. The lO-month prescription daims data paralleled the 4-month interval over which 
the 3 pill counts were conducted in order to minimise any time effects. The concordance 
between the cumulative medieation acquisition and pill count for overall medications was 
found to be 79%. This high concordance suggests that the rate with which patients refill 
their medication is usually consistent with the rate they consume them. 
A second miscIassification error could have been made in the assessment of 
outcome. It is possible that certain cases of cerebrovascular disease could not have been 
identified. The problem lies not in cases of cerebrovascular disease that were not selected, 
but rather in the selection of controls that are possibly unidentified cases. We cannot 
predict in which category of adherence these cases that were considered as controls by 
mistake would be in. This may appear at first to be a limit to our study since it is impossible 
75 
to predict the impact of this misclassification error on the association between adherence 
and cerebrovascular disease. However, we can show that the impact of this error can be 
minimised by the combination of several tools to identify the cases. 
As for diagnostic codes, one study evaluated their accuracy III administrative 
hospital discharge data.69 For ischemic stroke (lCD-9 codes 433, 434, and 436), the 
sensitivity was found to be 80%, specificity was 96%, and the positive predictive value was 
91 %, using the first 2 discharge diagnoses; while for intracerebral hemorrhage (code 431), 
those values were 85%, 94%, and 83%, respectively.69 Therefore, we believe that we were 
right in considering that using only diagnostic codes for cerebrovascular disease allow for a 
good sensitivity in identifying cerebrovascular events. 
Other differential misclassification errors could have been introduced in our study. 
The impact of this type of errors cannot be predicted, so they constitute limitations in our 
study. To start, we only have access to the medical file and pharmaceutical file five and two 
years, respectively, preceding the cohort entry date. It is therefore impossible to identify 
patients with previous cardiovascular events before this timeframe. Previous cardiovascular 
events increase the risk of cerebrovascular disease and are also linked to better compliance 
to treatment.20, 26, 57 One study do ne in Quebec found that primary prevention patients have 
an 18% increased risk of being non persistent to their statin therapy than secondary 
prevention patients.57 To minimise the probability of including secondary prevention 
patients in our study, we verified the absence of medical and diagnostic procedures related 
to CVD in the five years preceding the cohort entry date. In addition, we also verified the 
absence of medication linked to CVD in the two years preceding cohort entry. We believe 
that the effect of this error is minimal since the impact of a previous CVD on the risk of 
cerebrovascular disease is greatest in the year following the event and we go as far back as 
five years to make sure that the patients are CVD free. 20, 78, 80 
The third type of bias is confounding. Confounding occurs wh en the association 
between exposure and outcome is distorted by another factor that is linked with the 
exposure as well as the outcome. This factor is called a confounding variable. There is 
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confounding when the distribution of the confounding variable is not equivalent between 
the different exposure groups. A confounding variable can be responsible for a part or a11 of 
the association between exposure and outcome. 
The most important type of confounding In pharmacoepidemiology studies is 
confounding by indication. This type of confounding is due to the fact that patients who 
take a drug are generally different than those who don't due to the medical indication for 
which the drug was prescribed. The likelihood of confounding by indication in our study 
was reduced since the patients studied were aU receiving statin drugs. We chose to compare 
patients who were adherent to their statin regimen to those who were not. However, being 
adherent or not to treatment depends on the patient' s characteristics. Several studies have 
found that greater adherence to statins is associated with the presence of CVD risk 
factors. 14, 59, 60 We therefore tried to control for this bias by adjusting our results for risk 
factors such as male sex, age, socioeconomic status, hypertension, diabetes and the 
development of a CAD, CHF, PAD or other CVD du ring follow-up. 
As for unmeasured confounding variables, we assessed the robustness of our results 
by performing a sensitivity analysis. We used the Monte Carlo method proposed by 
Greenland and Steenland which considers that an unmeasured risk factor is less frequent 
among adherent than non adherent patients.76, 81 This type of analyses determined that the 
association between statin adherence and cerebrovascular disease is unlikely the result of 
confounding introduced by an unmeasured risk factor. We tried to find the strength of 
association between the unmeasured confounder and cerebrovascular disease as we11 as the 
difference of prevalence of this confounder amongst the two adherence groups that were 
necessary to invalidate our results. In summary, our results would be overturned when a 
confounder, such as smoking, has an OR for cerebrovascular disease of 3.0 or 4.0 for 
CUITent smokers and 2.0 for former smokers, in addition to a smoker prevalence in the high 
adherence group of 15% as compared to 25% in the low adherence group. We can conclude 
from this that our results are robust, since a bias of that magnitude is unlikely. Indeed, it has 
been shown that smoking increases the risk of stroke by 2 times and the prevalence of 
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smokers in Canada aged 45-64 years is 20% while it is of Il % for those 65 years and 
over.78, 82 No data is available on the prevalence of lifestyle habits and adherence to 
treatment for our population. However, one study performed in Korea evaluated the 
prevalence of certain confounders in 1019 dyslipidemic patients taking simvastatin.83 It 
found that among adherent patients, 16% were CUITent smokers, while 11% were former 
smokers; whereas among non adherent patients, those values were of 28% and 12%.83 It 
also found that 36% of adherent patients had a body mass index of 22-25 compared to 38% 
for non adherent patients, white 45% and 41 % had a body mass index of >25, for both 
. 1 83 groups respeCtive y. 
Although our analyses were adjusted for several confounding factors, it was 
impossible to adjust for clinical data such as cholesterol levels, arterial blood pressure and 
blood glucose levels. Fortunately, the lack of information on the patients' cholesterol 
values is not a great drawback due to the results of a study performed on patients with 
diabetes and dyslipidemia.84 This study found that adherence to statin therapy is closely 
associated to LDL cholesterol goal attainment and seems to increase substantially when 
adherence is >80%. Additionally, we checked the mean dose of statin prescribed to the 
patients. We know that patients who had a cerebrovascular event did not receive a different 
dose than controls. When we compared the mean dose in simvastatin equivalence, we 
found that it was of 22mg for the entire cohort. For patients followed for more than a year, 
the mean dose in simvastatin equivalence was of 23mg for cases and 22mg for controls. 
Although this difference is statistically significant, in terms of clinical efficacy it is of no 
importance. Consequently, the statin dose received by patients could not have influenced 
the results found. 
As for arterial blood pressure and blood glucose levels, it would have been 
preferable to adjust for their clinical values. We identified hypertension and diabetes on the 
basis of diagnostic codes and the use of medication. It is therefore impossible to determine 
amongst hypertensive and diabetic patients, those who control their blood pressure or their 
blood glucose levels from those who don't. However, to compensate for this lack of 
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information, we adjusted our analyses for diagnosed and untreated hypertension or 
diabetes, newly diagnosed patients (diagnosis within one year of index date) and adherence 
to medication for these pathologies «80% vs. ~80%). 
External validity 
Compared to clinical trials, our study provides more realistic results of the effect of 
statins on cerebrovascular disease in real-life practice. However, we must bear in mind that 
our study population doesn't perfectly represent the general population of Quebec. This 
does not invalidate the association between statin adherence and cerebrovascular disease 
for our study population, but it makes the extrapolation of our results to the entire 
population of Quebec difficult. According to data from the Quebec govemment, 47% of the 
Quebec population aged 45-85 years are covered by the provincial prescription drug 
insurance plan (about 40% of the Quebec population aged 45-64 years, and about 94% of 
those 65 years and 0Ider).85-87 In this age group, 6.1 % of Quebecers are welfare 
recipients.87, 88 In our study population, 16% of patients received social assistance. The 
other patients covered by the provincial prescription drug insurance plan are people who do 
not have access to private drug insurance. We can thus see that we only have data on a 
well-defined portion of the Quebec population. It is possible that people with access to 
private drug insurance are different than the patients inc1uded in our study. The prevalence 
of unmeasured risk factors (such as smoking, obesity, sedentary lifestyle) as well as 
measured risk factors (hypertension and diabetes) could be inferior in the general Quebec 
population aged 45 to 85 years. The proportion of men in the Quebec population is of 48%, 
which is similar to the 41 % found in our study population.87 Therefore, we can see that the 
major difference between our study population and the general Quebec population is the 
greater number of welfare recipients, which is accompanied by a slightly inferior male 
presence. However, since cerebrovascular disease mainly afflicts the elderly and since the 
RAMQ covers 94% of those 65 years of age and older, our results can be extrapolated to 
this population. 
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Proposais on Improving Study Design and Further Studies 
We have discussed how administrative databases are an important source of data for 
pharmacoepidemilogic studies. Nonetheless, an important limitation of these databases is 
the lack of information on potential confounders. Sensitivity analyses have permitted us to 
assess the impact of unmeasured risk factors. However, other methods could have been 
used to remedy the lack of data on lifestyle habits. One solution, developed more than 
twenty years ago is two-stage sampling.89 In the first stage, disease and exposure status are 
established for aIl patients using the administrative databases. The second stage consists of 
collecting data on confounding factors from a sample of the entire cohort. The selection of 
this sample can be done in two ways: either randomly or by using the balanced design 
method. The balanced design, in which an equal number of individuals is selected from 
each drug exposure/disease category, is usually the most efficient strategy by which to 
select the sample. One study even demonstrated the efficiency of this design using the 
RAMQ databases.90 From the information collected, it is possible to estimate the 
association between exposure and outcome that is adjusted for the confounding factors 
measured in the cohort sample. This information can be collected by looking at the medical 
ch arts of patients, by surveys or by interviews. Information would be collected on smoking, 
family history of CVD, level of physical activity and body mass index. 
Unfortunately, this method has its own difficulties. To start, authorization from the 
Commission d'accès à l'information du Québec must be obtained to have access to medical 
charts or to be able to interview patients. The problem with medical charts is that 
information on confounding factors may not have been documented. As for patient 
interviews, they can introduce recall bias. Indeed, cases would tend to remember more 
about their lifestyle habits than would controls. 
In terms of further studies, it would also be interesting to perform a cost-
effectiveness analysis and/or to assess the impact on healthcare costs. This would help to 
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determine whether it is economically worth treating aIl primary prevention patients or only 
a subgroup of patients, such as high-risk patients. The impact on healthcare costs analysis 
as weIl as the cost-effectiveness analysis of statins should consider the perspective of the 
RAMQ. As such, they should be performed using data on the resource use and costs for the 
treatment and symptoms of cerebrovascular disease as weB as the efficacy and safety of 
statins on cerebrovascular disease, while taking into consideration the size and 
characteristics of the population at risk. 
CONCLUSION 
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Non adherence to treatment is a prevalent problem of patients with chronic 
illnesses. Approximately half of the patients with a chronic disease have problems 
following their prescribed course of therapy to the extent that they are unable to obtain 
optimal clinical benefit.91 It is therefore important to know the consequences of poor 
adherence on the health outcomes of patients. This project aimed to evaluate the impact of 
adherence in terms of health outcome. 
In order to ob tain clinical benefits from a drug, a patient must be adherent as weIl as 
persistent to their therapy. At this present time, no study has evaluated the impact of statin 
adherence on cerebrovascular disease in primary prevention patients. Despite the fact that 
there are certain limitations to databases, it was essential to measure the real-life impact of 
statins. The results obtained from this study have estimated the benefits of statins in a 
setting outside the highly controlled environment of clinical trials. Moreover, they have 
shown the benefits that can be obtained in different subgroups of patients and subtypes of 
stroke. 
The results found can now be used as the basis for pharmacoeconomic studies, since 
poor adherence is associated with major economic issues. We already know that poor 
compliance to statins has a significant effect on healthcare costS.92 It is therefore important 
to try to quantify the impact of poor adherence on healthcare costs in terms of 
cerebrovascular disease prevention. In a setting of limited resources and unceasingly 
increasing healthcare costs, it is imperative to measure the impact of poor statin adherence 
on clinical as weIl as economic outcomes. 
Given the results obtained in this study, it is also necessary to develop new 
strategies aiming to improve adherence to therapy. These strategies would work best if they 
included the collaboration of physicians, nurses as weIl as community pharmacists. This 
web of medical professionals would then concentrate on providing medical support and 
encouragement to patients, so that they may achieve the most optimal use of their 
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treatment. It has been shown that interventions aimed at improving medication adherence 
have a significant impact on adherence to therapy and have a positive impact on health 
outcomes.93-95 
Results from this study and future studies will give insight on the best way to use 
statins so that the maximal number of patients can ob tain benefits from their treatment. 
What is now required is the development of strategies implicating diverse health 
professionals that aim to improve adherence and persistence to therapy. 
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TABLES 
II 
T bilA a e 1· ·d nnua mCI ence 0 fh . r osplta IsatlOns k . C d· 40 89 or stro e m ana lans to years 0 a~ 
40-49 50-59 60-69 70-79 80-89 Total 
years years years years years 
Men 0.041% 0.14% 0.39% 0.93% 1.8% 3.3% 
Women 0.036% 0.088% 0.24% 0.69% 1.5% 2.6% 
Total 0.077% 0.22% 0.63% 1.6% 3.3% 5.9% 
III 
T bl II S a e . d ampJ e Slze reqmre to measure t h d . e pnmary en lpomt 
Alpha Power Minimal Incidence of Non- Number 
RR to be disease in the exposedlexposed of cases 
detected non-exposed ratio 
group 
0.05 0.80 0.70 0.02 1 4346 
0.05 0.80 0.70 0.03 1 2916 
0.05 0.80 0.70 0.04 1 2201 
0.05 0.80 0.70 0.05 1 1773 
0.05 0.80 0.75 0.02 1 6422 
0.05 0.80 0.75 0.03 1 4312 
.·:idIQ5':. • "'(j:~()~i ·····b~f7~~{) "~);~':<"'6'O4!;;';;;:" .' ',~< '. :t~~i\0V> '" M. • •••• • •• • /')"'t&~:~ . / ':'ivL: .• , .' t>"%J:3~~it{~if~+l 
0.05 0.80 0.75 0.05 1 2625 
0.05 0.80 0.80 0.02 1 10288 
0.05 0.80 0.80 0.03 1 6912 
0.05 0.80 0.80 0.04 1 5225 
0.05 0.80 0.80 0.05 1 4214 
The non-exposedJexposed ratio was estimated from preliminary analyses that showed that 
approximately 50% of patients were at least 80% adherent to their statin therapy. 
IV 
Table III: Comparison of baseline characteristics of our cohort with those of primary 
prevention RCTs 
No. Patients 
Stroke (no.) 
Mean age t (continuous) 
Follow-up time (years) 
Men 
Social assistance t 
Diabetes mellitus:j: 
Hypertension:j: 
fAt treatment initiation 
RAMQ 
cohort 
112092 
3962 (3,5%) 
63 (+1- 10) 
2,9 
41% 
16% 
26% 
54% 
ASCOT-LLA*9 
10305 
210 (2,0%) 
63 
3,3 
81% 
NIA 
25% 
100% 
:j: ICD-9 or pharmacologic treatment in the year before cohort entry 
*Baseline characteristics for both treatment and placebo groups 
CARDS*ll 
2838 
56 (1,9%) 
62 (+1- 8) 
3,9 
68% 
NIA 
100% 
84% 
